Anti-CD33 antibodies and methods of use thereof

By designing antibodies with specific amino acid sequences, the affinity for CD33 is improved and the expression of CD33 cells is reduced, which solves the problems of insufficient affinity and low efficiency of existing antibodies in the treatment of CD33-related diseases, and achieves more effective disease treatment effects.

CN113801229BActive Publication Date: 2024-11-26艾利妥
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110955735.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-08-31
Filing Date
2019-08-30
Publication Date
2024-11-26
Estimated Expiration
2039-08-30

AI Technical Summary

Technical Problem

Existing anti-CD33 antibodies have problems with insufficient affinity and low cell surface expression in the treatment of related diseases, making it difficult to effectively target CD33-related diseases.

Method used

An antibody containing a specific amino acid sequence was developed, through improved heavy and light chain variable region design, the antibody's affinity for CD33 is improved, and the cell surface expression of CD33 is effectively reduced at low concentrations, including specific HVR- H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2 and HVR-L3 region sequences bind to Fab, Fab', F(ab')2, Fv or scFv fragments for specific binding to CD33 protein .

Benefits of technology

It has achieved a significant reduction in the cell surface level of CD33 at low concentrations, improved the dissociation constant of CD33, enhanced the expression of disease-related microglia markers, and provided a more effective treatment of CD33-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113801229B_ABST
    Figure CN113801229B_ABST
Patent Text Reader

Abstract

The present disclosure relates to anti-CD33 antibodies and methods of use thereof. The present disclosure generally relates to compositions comprising antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind to a CD33 polypeptide, e.g., mammalian CD33 or human CD33, and uses of such compositions in preventing, reducing the risk of, or treating an individual in need thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the invention application with the application date of August 30, 2019, Chinese application number 201980070570.9, and invention name “Anti-CD33 Antibodies and Methods of Use Thereof”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims the benefit of U.S. Provisional Application Serial No. 62 / 726,053, filed on August 31, 2018, which is hereby incorporated by reference in its entirety.

[0004] Submit sequence listing as ASCII text file

[0005] The following, submitted as an ASCII text file, is incorporated herein by reference in its entirety: Computer Readable Form (CRF) of the Sequence Listing (File Name: 735022002840SEQLIST.TXT, Record Date: August 26, 2019, Size: 112KB). Field of the Invention

[0006] The present disclosure relates to anti-CD33 antibodies and therapeutic uses of such antibodies. Background of the Invention

[0007] The myeloid cell surface antigen CD33 precursor (CD33), also known as Siglec-3, is a type 1 immunoglobulin-like transmembrane protein expressed on immune and hematopoietic cells, including immature and mature myeloid cells, dendritic cells, and microglia (Crocker et al. (2007) Nat Rev Immunol. 7:255–266; McMillan and Crocker (2008) Carbohydr Res. 343:2050–2056; Von Gunten and Bochner (2008) Ann NY Acad Sci. 1143:61–82; Handgretinger et al. (1993) Immunol Lett. 37:223–228; and Hernández-Caselles et al. (2006) J Leukoc Biol. 79:46–58). CD33 contains Ig-like C2-type (immunoglobulin-like) and Ig-like V-type (immunoglobulin-like) extracellular domains, as well as two ITIM-like motifs in its cytoplasmic domain. Three alternatively spliced ​​forms (isoforms) of CD33 have been identified, including a higher molecular weight variant designated CD33M and a smaller isoform CD33m that lacks the Ig-like V-type domain (ligand-binding site) and the disulfide bond connecting the V and C domains.

[0008] Genome-wide association studies (GWAS) of expanded cohorts (e.g., thousands of individuals) have linked the single nucleotide polymorphism (SNP) rs3865444 in CD33 to CC (AKA rs3826656) and rs3865444 AA Identified as a genetic modifier of risk for late-onset Alzheimer's disease (AD). In oncology, CD33 variants that result in reduced CD33 expression have been shown to be associated with improved survival in childhood acute myeloid leukemia (AML). Carrying the variant rs35112940 GG (Its relationship with rs3865444 AA The 3-year overall survival rate after remission was 84% ​​+ / - 8% for patients with the protective allele (variants in strong linkage disequilibrium), which was associated with lower expression of full-length CD33. The remission rate for the non-protective allele was 68% + / - 15%. Carriers of the protective allele also had a lower risk of relapse and a higher disease-free survival rate. Similarly, patients who were homozygous for the minor variant allele (TT) of rs12459419 (which was associated with a greater than 46% reduction in expression of full-length CD33) were more likely to have a good disease outcome than carriers of variants CC and CT (52% vs. 31%), and had much lower diagnostic native CD33 expression than other genotypes. This was true even in patients treated with anti-CD33 antibodies and toxic calicheamicin-γ derivatives (Mortland et al., (2013) Clin Cancer Res; 1–8). 2459419 showed a greater than 25% reduction in expression of full-length CD33. TT Carriers of the allele, and rs12459419 CT Carriers of the α-CD33 allele also show a reduced risk of Alzheimer's disease (Malik M. et al. (2015) Human Molecular Genetics, 1–14). This suggests that reducing CD33 expression or function may be beneficial in Alzheimer's disease and cancer.

[0009] Antibodies against CD33 have been described, for example, in US Pat. Nos. 7,342,110, 7,557,189, 8,119,787, 8,337,855, 8,124,069, 5,730,982, WO 2012 / 074097, WO 2004 / 043344, WO 1993 / 020848, WO 2012 / 045752, WO2007 / 014743, WO2003 / 093298, WO2011 / 036183, WO1991 / 009058, WO2008 / 058021, WO2011 / 038301, WO2016 / 201389, WO2016 / 201388, Hoyer et al. (2008) Am J Clin Pathol, 129:316-323, Rollins-Ravel and Roth (2012) Histopathology 60:933-942, Perez-Olivia et al. (2011) Glycobiol 21:757-770, Ferlasso et al. (2000) Eur J Immunol 30:827-833, Vitale et al. (2001) Proc Natl Acad Sci USA 98:5764-5769, Jandus et al. (2011) Biochem Pharmacol 82:323-332, O'Reilly and Paulson (2009) Trends Pharmcol Sci 30:240-248, Jurcic (2012) Curr Hematol Malig Rep 7:65-73, and Ricart (2011) Cl in Cancer Res 17:6417-6427.

[0010] Therefore, there is a need for therapeutic anti-CD33 antibodies to treat diseases, disorders, and conditions associated with undesirable CD33 activity.

[0011] All references cited herein, including patents, patent applications, and publications, are hereby incorporated by reference in their entirety. Summary of the Invention

[0012] The present disclosure generally relates to compositions comprising antibodies, such as monoclonal antibodies, chimeric antibodies, humanized antibodies, antibody fragments, etc., that specifically bind to human CD33, and methods of using such compositions.

[0013] Certain aspects of the present disclosure are based, at least in part, on the identification of anti-CD33 antibodies with improved and / or enhanced functional characteristics. In some embodiments, the anti-CD33 antibodies of the present disclosure comprise one or more improved and / or enhanced functional characteristics relative to a reference antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). In some embodiments, the anti-CD33 antibodies of the present disclosure have an affinity for CD33 (e.g., human CD33) that is greater than the affinity of the reference anti-CD33 antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). In some embodiments, the anti-CD33 antibodies of the present disclosure are effective at a half-maximal effective concentration (EC) that is lower than the half-maximal effective concentration (EC) of the reference antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). 50 ) binds to human cells, such as primary human dendritic cells, at a half-maximal effective concentration (EC) of SEQ ID NO: 3. In some embodiments, the anti-CD33 antibodies of the present disclosure bind to human cells, such as primary human dendritic cells, at a half-maximal effective concentration (EC) of SEQ ID NO: 4. 50 ) to reduce cellular levels of CD33 (e.g., lower or decrease cell surface levels).

[0014] Accordingly, in one aspect, the present disclosure relates to an antibody that binds to a CD33 protein, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: HVR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 8-30, HVR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 33, HVR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 39-40, HVR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 47, HVR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 53-55, and HVR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 58-62.

[0015] In another aspect, the present disclosure relates to an antibody that binds to a CD33 protein, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3 of the following antibodies: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25 5. 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C 7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 or 6C7H54.

[0016] In another aspect, the present disclosure relates to an antibody that binds to a CD33 protein, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3 of the following antibodies: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25 , 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7 H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 or 6C7H54.

[0017] In another aspect, the present disclosure relates to an antibody that binds to a CD33 protein, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3 of the following antibodies: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51 , 6C7H52, 6C7H53 or 6C7H54; and the light chain variable region comprises HVR-L1, HVR-L2 and HVR-L3 of the following antibodies: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7 H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6 C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 or 6C7H54.

[0018] In another aspect, the present disclosure relates to an antibody that binds to a CD33 protein, wherein the antibody comprises the heavy chain variable region of 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 7. 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7 H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C 7H53 or 6C7H54; and the antibody comprises the light chain variable region of the following antibodies: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7 H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6 C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 or 6C7H54.

[0019] In another aspect, the present disclosure relates to an antibody that binds to a CD33 protein, wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 68-93; and / or a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 97-103.

[0020] In another aspect, the present disclosure relates to an antibody that binds to a CD33 protein, wherein the antibody comprises the heavy chain variable region of 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 7. 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7 H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C 7H53 or 6C7H54; and the antibody comprises the light chain variable region of the following antibodies: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7 H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6 C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 or 6C7H54.

[0021] In another aspect, the disclosure relates to an isolated antibody that binds to CD33, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; and wherein the light chain variable region comprises: HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 61.

[0022] In another aspect, the disclosure relates to an isolated antibody that binds to CD33, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 83 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 102.

[0023] In another aspect, the disclosure relates to an isolated antibody that binds to CD33, wherein the antibody comprises:

[0024] (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 120 and a light chain comprising the amino acid sequence of SEQ ID NO: 122; or

[0025] (b) A heavy chain comprising the amino acid sequence of SEQ ID NO: 121 and a light chain comprising the amino acid sequence of SEQ ID NO: 122.

[0026] In some embodiments that may be combined with any of the preceding embodiments, the heavy chain variable region comprises one, two, three, or four framework regions selected from VH FR1, VH FR2, VH FR3, and VH FR4, wherein: VH FR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 5-6; VH FR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 31-32; VH FR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 34-36; and VH FR4 comprises the sequence of SEQ ID NO: 41; and the light chain variable region comprises one, two, three, or four framework regions selected from VL FR1, VL FR2, VL FR3, and VL FR4, wherein: VL FR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 42-46; VL FR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 48-51; VL FR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 56-57; and VL FR4 comprises a sequence selected from the group consisting of SEQ ID NOs: Sequences of the group consisting of ID NO:63-64.

[0027] In some embodiments that can be combined with any of the foregoing embodiments, the antibody belongs to IgG class, IgM class or IgA class. In some embodiments, the antibody belongs to IgG class and has IgG1, IgG2, IgG3 or IgG4 isotype. In some embodiments, the antibody has IgG4 isotype, and wherein the antibody is included in an S228P amino acid replacement at residue position 228, an F234A amino acid replacement at residue position 234, and an L235A amino acid replacement at residue position 235, wherein the numbering of the residue positions is according to EU numbering. In some embodiments, the antibody is included in one or more amino acid replacements at a residue position selected from the group consisting of: C127S, L234A, L234F, L235A, L235E, S267E, K322A, L328F, A330S, P331S, E345R, E430G, S440Y and any combination thereof in the Fc region, wherein the numbering of the residues is according to EU numbering. In some embodiments, the Fc region comprises an amino acid substitution at position E430G, wherein the numbering of the residue positions is according to EU numbering; the Fc region comprises an amino acid substitution at positions L234A, L235A, and P331A, wherein the numbering of the residue positions is according to EU numbering; the Fc region comprises an amino acid substitution at positions L234A, L235A, P331A, and E430G, wherein the numbering of the residue positions is according to EU numbering; the Fc region comprises an amino acid substitution at positions K322A and E430G, wherein the numbering of the residue positions is according to EU numbering; the Fc region comprises an amino acid substitution at positions P331S and E430G, wherein the numbering of the residue positions is according to EU numbering; the Fc region comprises an amino acid substitution at positions A330S, P331S, and E430G, wherein the numbering of the residue positions is according to EU numbering; the Fc region comprises an amino acid substitution at positions K322A, A the Fc region comprises amino acid substitutions at positions K322A, P331S and E430G, wherein the numbering of the residue positions is according to the EU numbering; the Fc region comprises an amino acid substitution at position E430G, wherein the numbering of the residue positions is according to the EU numbering; the Fc region comprises amino acid substitutions at positions A330S, P331S and E430G, wherein the numbering of the residue positions is according to the EU numbering; the Fc region comprises amino acid substitutions at positions S267E and L328F, wherein the numbering of the residue positions is according to the EU numbering; the Fc region comprises an amino acid substitution at position C127S, wherein the numbering of the residue positions is according to the EU numbering; or the Fc region comprises amino acid substitutions at positions E345R, E430G and S440Y, wherein the numbering of the residue positions is according to the EU numbering.

[0028] In some embodiments that may be combined with any of the preceding embodiments, the CD33 protein is a mammalian or human protein. In some embodiments, the CD33 protein is a wild-type protein. In some embodiments, the CD33 protein is a naturally occurring variant. In some embodiments that may be combined with any of the preceding embodiments, the CD33 protein is expressed on one or more cells selected from the group consisting of human dendritic cells, human macrophages, human monocytes, human osteoclasts, human neutrophils, human T cells, human helper T cells, human cytotoxic T cells, human granulocytes, and human microglia.

[0029] In some embodiments that may be combined with any of the preceding embodiments, the antibody specifically binds to a human CD33 protein. In some embodiments, the antibody binds to a human CD33 protein and does not cross-react with a CD33 ortholog or homolog from another species. In some embodiments that may be combined with any of the preceding embodiments, the antibody is an antibody fragment that binds to an epitope comprising amino acid residues on a human CD33 or mammalian CD33 protein. In some embodiments that may be combined with any of the preceding embodiments, the antibody is an antibody fragment that binds to one or more human proteins selected from the group consisting of: human CD33, naturally occurring variants of human CD33, and disease variants of human CD33. In some embodiments, the antibody fragment is cross-linked with a second antibody fragment that binds to one or more human proteins selected from the group consisting of: human CD33, naturally occurring variants of human CD33, and disease variants of human CD33. In some embodiments, the fragment is a Fab, Fab', Fab'-SH, F(ab')2, Fv, or scFv fragment.

[0030] In some embodiments that may be combined with any of the foregoing embodiments, the antibody is a humanized antibody, a bispecific antibody, a monoclonal antibody, a multivalent antibody, a conjugated antibody, or a chimeric antibody. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a bispecific antibody that recognizes a first antigen and a second antigen. In some embodiments, the first antigen is CD33 and the second antigen is: an antigen that promotes transport across the blood-brain barrier; an antigen that promotes transport across the blood-brain barrier selected from the group consisting of transferrin receptor (TR), insulin receptor (HIR), insulin-like growth factor receptor (IGFR), low-density lipoprotein receptor-related proteins 1 and 2 (LPR-1 and LPR-2), diphtheria toxin receptor, CRM197, alpaca single domain antibody, TMEM 30(A), protein transduction domain, TAT, Syn-B, penetratin, polyarginine peptide, angiopep peptide and ANG1005; a pathogenic factor selected from the group consisting of: a pathogenic peptide or protein and a pathogenic nucleic acid, wherein the pathogenic peptide or protein is selected from the group consisting of beta-amyloid protein, oligomeric beta-amyloid protein, beta-amyloid protein plaque, amyloid precursor protein or its fragment, Tau, IAPP, alpha-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin protein, calcitonin, superoxide dismutase, ataxin, ataxin 1, ataxin 2, ataxin 3, ataxin 7, ataxin 8, ataxin 10, Lewy body (Lewy body) body), atrial natriuretic peptide, amylin, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, β2-microglobulin, gelsolin, keratin, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation products, dipeptide repeat (DPR) peptides, glycine-alanine (GA) repeat peptides, glycine-proline (GP) repeat peptides, glycine-arginine (GR) repeat peptides, proline-alanine (PA) repeat peptides, ubiquitin, and proline-arginine (PR) repeat peptides, and the pathogenic nucleic acid is antisense GGCCCC (G2C4) repeat-expanded RNA;A ligand and / or protein expressed on an immune cell, wherein the ligand and / or protein is selected from the group consisting of: CD40, OX40, ICOS, CD28, CD137 / 4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7-H4, HVEM, LIGHT, BTLA, CD38, TIGIT, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR, LAG3, DR5, CD39, CD70, CD73, TREM1, TREM2, Siglec-5, Siglec-7, Siglec-9, Siglec-11, SirpA, CD47, CSF1-receptor, and phosphatidylserine; and a protein, lipid, polysaccharide, or glycolipid expressed on one or more tumor cells.

[0031] In some embodiments that may be combined with any of the preceding embodiments, the antibody is used in combination with one or more antibodies that specifically bind to a pathogenic factor selected from the group consisting of a pathogenic peptide, a pathogenic protein, beta-amyloid protein, oligomeric beta-amyloid protein, beta-amyloid protein plaques, amyloid precursor protein or fragments thereof, Tau, IAPP, alpha-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), prion protein, PrPSc, huntingtin protein, calcitonin, superoxide dismutase, ataxia Dysregulation, ataxin 1, ataxin 2, ataxin 3, ataxin 7, ataxin 8, ataxin 10, Lewy bodies, atrial natriuretic peptide, islet amylin, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, β2-microglobulin, gelsolin, keratoepithelin, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation product, dipeptide repeat (DPR) peptide, glycine-alanine (GA) repeat peptides, glycine-proline (GP) repeat peptides, glycine-arginine (GR) repeat peptides, proline-alanine (PA) repeat peptides, ubiquitin and proline-arginine (PR) repeat peptides and any combination thereof; or used in combination with one or more antibodies that bind to immunomodulatory proteins selected from the group consisting of CD40, OX40, ICOS, CD28, CD137 / 4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7-H 4. HVEM, LIGHT, BTLA, CD38, TIGIT, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR3, DR5, CD39, CD70, CD73, LAG3, TREM1, TREM2, Siglec-5, Siglec-7, Siglec-9, Siglec-11, SirpA, CD47, CSF1-receptor, phosphatidylserine, pathogenic nucleic acids, antisense GGCCCC (G2C4) repeat expansion RNA, and any combination thereof.

[0032] In some embodiments that may be combined with any of the preceding embodiments, the antibody has a dissociation constant (K D ) is at least 1.8-fold lower than an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4, wherein the K D Determined by biofilm interferometry.

[0033] In some embodiments that may be combined with any of the preceding embodiments, the antibody has a dissociation constant (K D ) is in the range of about 2 nM to about 200 pM, or less than about 200 pM, and wherein the K D Determined by biofilm interferometry.

[0034] In some embodiments that may be combined with any of the preceding embodiments, the antibody reduces cell surface levels of CD33. In some embodiments, CD33 is expressed on the surface of human dendritic cells. In some embodiments, the antibody reduces cell surface levels of CD33 in vitro. In some embodiments, the antibody reduces cell surface levels of CD33 in vitro at a half maximal effective concentration (EC) of less than 40 pM as measured by flow cytometry. 50 ) reduces cell surface levels of CD33.

[0035] In some embodiments that may be combined with any of the preceding embodiments, the antibody increases expression of one or more disease-associated microglial (DAM) markers.

[0036] In some embodiments, the one or more DAM markers are ApoE3, Tyrobp, B2m, Trem2, Cst7, Ctsl, Lpl, Cd9, Axl, Csfl, Ccl6, Itgax, Clec7a, Lilrb4, Timp2, or any combination thereof. In some embodiments that may be combined with any of the preceding embodiments, the antibody competes for binding to human CD33 with one or more antibodies selected from the group consisting of 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof.

[0037] In some embodiments that may be combined with any of the preceding embodiments, the antibody binds to substantially the same epitope of CD33 as, or an overlapping epitope of CD33 as, an antibody selected from the group consisting of: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 and 6C7H54.

[0038] In some embodiments that may be combined with any of the preceding embodiments, the antibody has an Fc region comprising the amino acid sequence of SEQ ID NO:118.

[0039] In some embodiments that may be combined with any of the preceding embodiments, the anti-CD33 antibodies of the present disclosure comprise a heavy chain variable domain and a light chain variable domain, wherein (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 8, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 38, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 52, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (b) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 8, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (c) HVR-H1 comprises the amino acid sequence of SEQ ID NO: NO:9, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:54, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (d) HVR-H1 comprises the amino acid sequence of SEQ ID NO:9, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (e) HVR-H1 comprises the amino acid sequence of SEQ ID NO:9, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:55, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58;(f) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 10, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (g) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 11, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (h) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 12, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (i) HVR-H1 comprises the amino acid sequence of SEQ ID NO:13, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (j) HVR-H1 comprises the amino acid sequence of SEQ ID NO:14, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: (k) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 15, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58;(l) HVR-H1 comprises the amino acid sequence of SEQ ID NO:16, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (m) HVR-H1 comprises the amino acid sequence of SEQ ID NO:17, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (n) HVR-H1 comprises the amino acid sequence of SEQ ID NO:18, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (o) HVR-H1 comprises the amino acid sequence of SEQ ID NO:19, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (p) HVR-H1 comprises the amino acid sequence of SEQ ID NO:20, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: (q) HVR-H1 comprises the amino acid sequence of SEQ ID NO:21, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58;(r) HVR-H1 comprises the amino acid sequence of SEQ ID NO:22, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (s) HVR-H1 comprises the amino acid sequence of SEQ ID NO:23, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (t) HVR-H1 comprises the amino acid sequence of SEQ ID NO:24, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (u) HVR-H1 comprises the amino acid sequence of SEQ ID NO:25, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (v) HVR-H1 comprises the amino acid sequence of SEQ ID NO:26, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: (w) HVR-H1 comprises the amino acid sequence of SEQ ID NO:27, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58;(x) HVR-H1 comprises the amino acid sequence of SEQ ID NO:28, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (y) HVR-H1 comprises the amino acid sequence of SEQ ID NO:29, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:59; (z) HVR-H1 comprises the amino acid sequence of SEQ ID NO:29, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:60; (aa) HVR-H1 comprises the amino acid sequence of SEQ ID NO:29, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:61; (bb) HVR-H1 comprises the amino acid sequence of SEQ ID NO:29, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:62;(cc) HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:40, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:59; (dd) HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:40, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:60; (ee) HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: NO:40, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:61; (ff) HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:40, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:62; (gg) HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:60;(hh) HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:62; (ii) HVR-H1 comprises the amino acid sequence of SEQ ID NO:23, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:60; (jj) HVR-H1 comprises the amino acid sequence of SEQ ID NO:23, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:62; (kk) HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:59; (ll) HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:61;(mm) HVR-H1 comprises the amino acid sequence of SEQ ID NO:28, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:59; and (nn) HVR-H1 comprises the amino acid sequence of SEQ ID NO:28, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:61.;

[0040] In some embodiments that may be combined with any of the preceding embodiments, the anti-CD33 antibodies of the present disclosure comprise a light chain variable region comprising an amino acid sequence selected from any one of SEQ ID NOs: 94-103; and / or a heavy chain variable domain comprising an amino acid sequence selected from any one of SEQ ID NOs: 65-93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 94; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 94; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 66. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 95; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 95; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 67. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 95; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 66. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 96; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 96; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 67. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 68. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 98; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 69. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 69. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 94; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 99; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 69. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 70.In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 71. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 72. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 73. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 77. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 78. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 79. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 80. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 81. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 82. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 83. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 84.In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 85. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 86. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 87. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 88. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 89. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 89. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 89. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 89. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 90. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 90. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 90. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 90. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 91. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 91.In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 91. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 91. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 83. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 83. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 83. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 83.

[0041] In another aspect, the disclosure relates to an isolated nucleic acid comprising a nucleic acid sequence encoding any of the antibodies described herein.

[0042] In another aspect, the present disclosure relates to a vector comprising any of the nucleic acids described herein. In some embodiments, the vector is an expression vector and / or a display vector.

[0043] In another aspect, the disclosure relates to an isolated host cell comprising any of the nucleic acids or vectors described herein.

[0044] In another aspect, the present disclosure relates to a method for producing an antibody that binds to CD33, comprising culturing any of the host cells described herein, thereby producing the antibody. In some embodiments, the method further comprises recovering the antibody produced by the cell.

[0045] In another aspect, the disclosure relates to antibodies produced by any of the methods described herein.

[0046] In another aspect, the present disclosure relates to a pharmaceutical composition comprising any of the antibodies described herein and a pharmaceutically acceptable carrier. In some embodiments, the present disclosure relates to the use of any of the antibodies described herein in the preparation of a medicament.

[0047] On the other hand, the present invention relates to a method for preventing a disease, disorder or injury, reducing the risk of the disease, disorder or injury, or treating the disease, disorder or injury, wherein the disease, disorder or injury is selected from the group consisting of: dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, tauopathy, infection and cancer, the method comprising administering a therapeutically effective amount of any antibody described herein to an individual in need thereof. In some embodiments, the disease, disorder or injury is cancer. In some embodiments, the cancer is selected from the group consisting of: bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML) and multiple myeloma. In some embodiments, the present disclosure relates to the use of any of the antibodies described herein for the preparation of a medicament for preventing, reducing the risk of, or treating a disease, disorder, or injury selected from the group consisting of: dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, tauopathy, infection, and cancer. In some embodiments, the disease, disorder, or injury is cancer. In some embodiments, the cancer is selected from the group consisting of: bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), and multiple myeloma.

[0048] The present invention relates to the following embodiments.

[0049] 1. An isolated antibody that binds to CD33, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: HVR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 8-30, HVR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 33, HVR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 39-40, HVR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 47, HVR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 53-55, and HVR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 58-62.

[0050] 2. An isolated antibody that binds to CD33, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3 of the following antibodies: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26 7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H 40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 or 6C7H54.

[0051] 3. An isolated antibody that binds to CD33, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3 of the following antibodies: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26 7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H 40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 or 6C7H54.

[0052] 4. An isolated antibody that binds to CD33, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3 of the following antibodies: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24 , 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H 38. 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C 7H52, 6C7H53 or 6C7H54; and the light chain variable region comprises HVR-L1, HVR-L2 and HVR-L3 of the following antibodies: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H 27. 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C 7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 or 6C7H54.

[0053] 5. The antibody of embodiment 4, wherein the antibody comprises the heavy chain variable region of the following antibodies: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28 8. 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C 7H41,6C7H42,6C7H43,6C7H44,6C7H45,6C7H46,6C7H47,6C7H48,6C7H49,6C7H50,6C7H51,6C7H52,6C7H53 or 6C7H54; and the antibody comprises the light chain variable region of the following antibodies: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29 9. 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C 7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 or 6C7H54.

[0054] 6. The antibody of any one of embodiments 1-5, wherein the heavy chain variable region comprises one, two, three, or four framework regions selected from VH FR1, VH FR2, VH FR3, and VH FR4, wherein: VH FR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 5-6; VH FR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 31-32; VH FR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 34-36; and VH FR4 comprises a sequence of SEQ ID NO: 41; and the light chain variable region comprises one, two, three, or four framework regions selected from VL FR1, VL FR2, VL FR3, and VL FR4, wherein: VL FR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 42-46; VL FR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 48-51; VL FR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 56-57; and VL FR4 comprises a sequence selected from the group consisting of SEQ ID NOs: The sequence of the group consisting of NO:63-64.

[0055] 7. The antibody of any one of embodiments 1-6, wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 68-93; and / or a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 97-103.

[0056] 8. The antibody of embodiment 7, wherein the antibody comprises the heavy chain variable region of the following antibodies: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28 8. 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C 7H41,6C7H42,6C7H43,6C7H44,6C7H45,6C7H46,6C7H47,6C7H48,6C7H49,6C7H50,6C7H51,6C7H52,6C7H53 or 6C7H54; and the antibody comprises the light chain variable region of the following antibodies: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29 9. 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C 7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 or 6C7H54.

[0057] 9. An isolated antibody that binds to CD33, wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 68-93; and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 97-103.

[0058] 10. The antibody of embodiment 9, wherein the antibody comprises the heavy chain variable region of the following antibodies: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H 28. 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6 C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 or 6C7H54; and the antibody comprises the light chain variable region of the following antibodies: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29 9. 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C 7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 or 6C7H54.

[0059] 11. The antibody of any one of embodiments 1-10, wherein the antibody is a monoclonal antibody.

[0060] 12. The antibody of any one of embodiments 1-11, wherein the antibody is of the IgG, IgM, or IgA class.

[0061] 13. The antibody of embodiment 12, wherein the antibody is of the IgG class and has an IgG1, IgG2, IgG3 or IgG4 isotype.

[0062] 14. The antibody of embodiment 13, wherein the antibody comprises one or more amino acid substitutions at a residue position in the Fc region selected from the group consisting of: C127S, L234A, L234F, L235A, L235E, S267E, K322A, L328F, A330S, P331S, E345R, E430G, S440Y, and any combination thereof, wherein the numbering of the residues is according to EU numbering.

[0063] 15. The antibody of embodiment 13, wherein the antibody has an IgG4 isotype, and wherein the antibody comprises an S228P amino acid substitution at residue position 228, a F234A amino acid substitution at residue position 234, and a L235A amino acid substitution at residue position 235, wherein the numbering of the residue positions is according to EU numbering.

[0064] 16. The antibody of embodiment 15, wherein:

[0065] (a) the Fc region comprises an amino acid substitution at position E430G, wherein the numbering of residue positions is according to EU numbering;

[0066] (b) the Fc region comprises amino acid substitutions at positions L234A, L235A, and P331A, wherein the numbering of the residue positions is according to EU numbering;

[0067] (c) the Fc region comprises amino acid substitutions at positions L234A, L235A, P331A, and E430G, wherein the numbering of the residue positions is according to EU numbering;

[0068] (d) the Fc region comprises amino acid substitutions at positions K322A and E430G, wherein the numbering of the residue positions is according to EU numbering;

[0069] (e) the Fc region comprises amino acid substitutions at positions P331S and E430G, wherein the numbering of the residue positions is according to EU numbering;

[0070] (f) the Fc region comprises amino acid substitutions at positions A330S, P331S, and E430G, wherein the numbering of the residue positions is according to EU numbering;

[0071] (g) the Fc region comprises amino acid substitutions at positions K322A, A330S, and P331S, wherein the numbering of the residue positions is according to EU numbering;

[0072] (h) the Fc region comprises amino acid substitutions at positions K322A, P331S, and E430G, wherein the numbering of the residue positions is according to EU numbering;

[0073] (i) the Fc region comprises an amino acid substitution at position E430G, wherein the numbering of residue positions is according to EU numbering;

[0074] (j) the Fc region comprises amino acid substitutions at positions A330S, P331S, and E430G, wherein the numbering of the residue positions is according to EU numbering;

[0075] (k) the Fc region comprises amino acid substitutions at positions S267E and L328F, wherein the numbering of the residue positions is according to EU numbering;

[0076] (1) the Fc region comprises an amino acid substitution at position C127S, wherein the numbering of residue positions is according to EU numbering;

[0077] (m) the Fc region comprises amino acid substitutions at positions E345R, E430G, and S440Y, wherein the numbering of the residue positions is according to EU numbering;

[0078] (n) the Fc region comprises an amino acid substitution at position P331S, wherein the numbering of residue positions is according to EU numbering; or

[0079] (o) the Fc region comprises amino acid substitutions at positions L234A, L235A, P331S, wherein the numbering of the residue positions is according to EU numbering.

[0080] 17. The antibody of any one of embodiments 1-16, wherein the CD33 protein is a mammalian or human protein.

[0081] 18. The antibody of any one of embodiments 1-17, wherein the CD33 protein is a wild-type protein.

[0082] 19. The antibody of any one of embodiments 1-17, wherein the CD33 protein is a naturally occurring variant.

[0083] 20. The antibody of any one of embodiments 1-19, wherein the CD33 protein is expressed on one or more cells selected from the group consisting of: human dendritic cells, human macrophages, human monocytes, human osteoclasts, human neutrophils, human T cells, human helper T cells, human cytotoxic T cells, human granulocytes, and human microglia.

[0084] 21. The antibody of any one of embodiments 1-20, wherein the antibody specifically binds to human CD33 protein.

[0085] 22. The antibody of any one of embodiments 1-21, wherein the antibody is an antibody fragment that binds to an epitope comprising amino acid residues on a human CD33 protein or a mammalian CD33 protein.

[0086] 23. The antibody of any one of embodiments 1-22, wherein the antibody is an antibody fragment that binds to one or more human proteins selected from the group consisting of: human CD33, naturally occurring variants of human CD33, and disease variants of human CD33.

[0087] 24. The antibody of embodiment 22 or embodiment 23, wherein the antibody fragment is cross-linked to a second antibody fragment that binds to one or more human proteins selected from the group consisting of: human CD33, naturally occurring variants of human CD33, and disease variants of human CD33.

[0088] 25. The antibody of any one of embodiments 22-24, wherein the fragment is a Fab, Fab', Fab'-SH, F(ab')2, Fv, or scFv fragment.

[0089] 26. The antibody of any one of embodiments 1-25, wherein the antibody is a humanized antibody, a bispecific antibody, a monoclonal antibody, a multivalent antibody, a conjugated antibody, or a chimeric antibody.

[0090] 27. The antibody of any one of embodiments 1-26, wherein the antibody is a monoclonal antibody.

[0091] 28. The antibody of any one of embodiments 1-26, wherein the antibody is a bispecific antibody that recognizes a first antigen and a second antigen.

[0092] 29. The antibody of embodiment 28, wherein the first antigen is CD33 and the second antigen is:

[0093] (a) Antigens that promote transport across the blood-brain barrier;

[0094] (b) an antigen that promotes transport across the blood-brain barrier selected from the group consisting of transferrin receptor (TR), insulin receptor (HIR), insulin-like growth factor receptor (IGFR), low-density lipoprotein receptor-related proteins 1 and 2 (LPR-1 and LPR-2), diphtheria toxin receptor, CRM197, alpaca single domain antibody, TMEM 30 (A), protein transduction domain, TAT, Syn-B, penetratin, polyarginine peptide, angiopep peptide, and ANG1005;

[0095] (c) a pathogenic factor selected from the group consisting of: a pathogenic peptide or protein and a pathogenic nucleic acid, wherein the pathogenic peptide or protein is selected from the group consisting of: beta-amyloid protein, oligomeric beta-amyloid protein, beta-amyloid protein plaque, amyloid precursor protein or its fragment, Tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin protein, calcitonin, superoxide dismutase, ataxin, ataxin 1, ataxin 2, ataxin 3, ataxin 7, ataxin 8, ataxin 10, Lewy body, heart disease, natriuretic peptide, islet amylin, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, β2 microglobulin, gelsolin, keratoepithelin, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation products, dipeptide repeat (DPR) peptides, glycine-alanine (GA) repeat peptides, glycine-proline (GP) repeat peptides, glycine-arginine (GR) repeat peptides, proline-alanine (PA) repeat peptides, ubiquitin and proline-arginine (PR) repeat peptides, and the pathogenic nucleic acid is antisense GGCCCC (G2C4) repeat expansion RNA;

[0096] (d) ligands and / or proteins expressed on immune cells, wherein the ligands and / or proteins are selected from the group consisting of: CD40, OX40, ICOS, CD28, CD137 / 4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7-H4, HVEM, LIGHT, BTLA, CD38, TIGIT, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR, LAG3, DR5, CD39, CD70, CD73, TREM1, TREM2, Siglec-5, Siglec-7, Siglec-9, Siglec-11, SirpA, CD47, CSF1-receptor, and phosphatidylserine; and

[0097] (e) a protein, lipid, polysaccharide or glycolipid expressed on one or more tumor cells.

[0098] 30. The antibody of any one of embodiments 1-29, wherein the antibody is used in combination with one or more antibodies that specifically bind to a pathogenic factor, the pathogenic factor being selected from the group consisting of: a pathogenic peptide, a pathogenic protein, beta-amyloid protein, oligomeric beta-amyloid protein, beta-amyloid protein plaques, amyloid precursor protein or fragments thereof, Tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), prion protein, PrPSc, huntingtin protein, calcitonin, superoxide dismutase , ataxin, ataxin 1, ataxin 2, ataxin 3, ataxin 7, ataxin 8, ataxin 10, Lewy bodies, atrial natriuretic peptide, islet amyloid polypeptide, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, β2-microglobulin, gelsolin, keratoepithelin, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation product, dipeptide repeat (DPR) peptide, glycine-alanine or used in combination with one or more antibodies that bind to immunomodulatory proteins selected from the group consisting of: CD40, OX40, ICOS, CD28, CD137 / 4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7- H4, HVEM, LIGHT, BTLA, CD38, TIGIT, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR3, DR5, CD39, CD70, CD73, LAG3, TREM1, TREM2, Siglec-5, Siglec-7, Siglec-9, Siglec-11, SirpA, CD47, CSF1-receptor, phosphatidylserine, pathogenic nucleic acids, antisense GGCCCC(G2C4) repeat expansion RNA, and any combination thereof.

[0099] 31. The antibody of any one of embodiments 1-30, wherein the dissociation constant (K) of the antibody for human CD33 is D ) is at least 1.8-fold lower than an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4, wherein the K D Determined by biofilm interferometry.

[0100] 32. The antibody of any one of embodiments 1-31, wherein the dissociation constant (K) of the antibody for human CD33 is D ) is in the range of about 2 nM to about 200 pM, or less than about 200 pM, and wherein the K D Determined by biofilm interferometry.

[0101] 33. The antibody of any one of embodiments 1-32, wherein the antibody reduces cell surface levels of CD33.

[0102] 34. The antibody of embodiment 33, wherein the CD33 is expressed on the surface of human dendritic cells.

[0103] 35. The antibody of embodiment 33 or embodiment 34, wherein the antibody reduces cell surface levels of CD33 in vitro.

[0104] 36. The antibody of any one of embodiments 33-35, wherein the antibody is expressed in vitro at a half-maximal effective concentration (EC) of less than 40 pM as measured by flow cytometry. 50 ) reduces cell surface levels of CD33.

[0105] 37. The antibody of any one of embodiments 1-36, wherein the antibody increases expression of one or more disease-associated microglial (DAM) markers.

[0106] 38. The antibody of embodiment 37, wherein the one or more DAM markers are ApoE3, Tyrobp, B2m, Trem2, Cst7, Ctsl, Lpl, Cd9, Axl, Csf1, Ccl6, Itgax, Clec7a, Lilrb4, Timp2, or any combination thereof.

[0107] 39. The antibody of any one of embodiments 1-38, wherein the antibody competes for binding to CD33 with one or more antibodies selected from the group consisting of 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof.

[0108] 40. The antibody of any of embodiments 1-38, wherein the antibody binds to substantially the same CD33 epitope or an overlapping CD33 epitope as an antibody selected from the group consisting of: 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 and 6C7H54.

[0109] 41. The antibody of any one of embodiments 1-40, wherein the antibody comprises an Fc region comprising the amino acid sequence of SEQ ID NO: 118.

[0110] 42. An isolated antibody that binds to CD33, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: HVR-H1 comprising the amino acid sequence of SEQ ID NO:23, HVR-H2 comprising the amino acid sequence of SEQ ID NO:33, HVR-H3 comprising the amino acid sequence of SEQ ID NO:39; and wherein the light chain variable region comprises: HVR-L1 comprising the amino acid sequence of SEQ ID NO:47, HVR-L2 comprising the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:61.

[0111] 43. An isolated antibody that binds to CD33, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 83 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 102.

[0112] 44. An isolated antibody that binds to CD33, wherein the antibody comprises

[0113] (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 120 and a light chain comprising the amino acid sequence of SEQ ID NO: 122; or

[0114] (b) A heavy chain comprising the amino acid sequence of SEQ ID NO: 121 and a light chain comprising the amino acid sequence of SEQ ID NO: 122.

[0115] 45. The antibody of any one of embodiments 41-44, wherein the antibody specifically binds to human CD33 protein.

[0116] 46. ​​The antibody of any one of embodiments 41-45, wherein the dissociation constant (K) of the antibody for human CD33 is D ) is at least 1.8-fold lower than that of an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4, wherein the K D Determined by biofilm interferometry.

[0117] 47. The antibody of any one of embodiments 41-46, wherein the dissociation constant (K) of the antibody for human CD33 is D ) is in the range of about 2 nM to about 200 pM, or less than about 200 pM, and wherein the K D Determined by biofilm interferometry.

[0118] 48. The antibody of any one of embodiments 41-47, wherein the antibody reduces cell surface levels of CD33.

[0119] 49. The antibody of embodiment 48, wherein the CD33 is expressed on the surface of human dendritic cells.

[0120] 50. The antibody of embodiment 48 or embodiment 49, wherein the antibody reduces cell surface levels of CD33 in vitro.

[0121] 51. The antibody of any one of embodiments 48-50, wherein the antibody is expressed in vitro at a half-maximal effective concentration (EC) of less than 40 pM as measured by flow cytometry. 50 ) reduces cell surface levels of CD33.

[0122] 52. The antibody of any one of embodiments 41-51, wherein the antibody increases expression of one or more disease-associated microglial (DAM) markers.

[0123] 53. The antibody of embodiment 52, wherein the one or more DAM markers are ApoE3, Tyrobp, B2m, Trem2, Cst7, Ctsl, Lpl, Cd9, Axl, Csf1, Ccl6, Itgax, Clec7a, Lilrb4, Timp2, or any combination thereof.

[0124] 54. An isolated nucleic acid comprising a nucleic acid sequence encoding the antibody of any one of embodiments 1-53.

[0125] 55. A vector comprising the nucleic acid of embodiment 54.

[0126] 56. An isolated host cell comprising the vector of embodiment 55.

[0127] 57. A method for producing an antibody that binds to CD33, the method comprising culturing the cell of embodiment 56, thereby producing the antibody.

[0128] 58. The method of embodiment 57, further comprising recovering the antibody produced by the cell.

[0129] 59. An isolated antibody that binds to CD33 produced by the method of embodiment 57 or 58.

[0130] 60. A pharmaceutical composition comprising the antibody of any one of embodiments 1-53 and 59 and a pharmaceutically acceptable carrier.

[0131] 61. A method of preventing, reducing the risk of, or treating a disease, disorder, or injury selected from the group consisting of dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, tauopathy, infection, and cancer, comprising administering to an individual in need thereof a therapeutically effective amount of the antibody of any one of embodiments 1-53 and 59.

[0132] 62. The method of embodiment 61, wherein the disease, disorder or injury is cancer.

[0133] 63. The method of embodiment 62, wherein the cancer is selected from the group consisting of bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), and multiple myeloma.

[0134] It should be understood that one, some or all of the features of the various embodiments described herein may be combined to form other embodiments of the present invention. These and other aspects of the present invention will become apparent to those skilled in the art. These and other embodiments of the present invention will be further described by the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0135] Figure 1 Presented are data showing that anti-CD33 antibodies of the present disclosure bind to primary human dendritic cells.

[0136] Figure 2 Presented are data showing that anti-CD33 antibodies of the present disclosure downregulate cell surface levels of CD33 in human dendritic cells.

[0137] Figure 3 Presented are data showing that anti-CD33 antibodies of the present disclosure bind to primary human dendritic cells.

[0138] Figure 4 Data showing that anti-CD33 antibodies of the present disclosure bind to human CD33 and cynomolgus CD33 proteins are presented.

[0139] Figure 5 Presented are data showing that anti-CD33 antibodies of the present disclosure downregulate cell surface levels of CD33 in human dendritic cells.

[0140] Figure 6A and Figure 6BData showing that anti-CD33 antibodies of the present disclosure bind to recombinant human CD33 are presented.

[0141] Figure 7 Data showing that anti-CD33 antibodies of the present disclosure bind to primary human dendritic cells are presented.

[0142] Figure 8A and Figure 8B Shown are data comparing the reduction of cell surface levels of CD33 in dendritic cells by various anti-CD33 antibodies of the disclosure.

[0143] Figure 9 Data showing that anti-CD33 antibody variants of the present disclosure bind to primary human dendritic cells are presented.

[0144] Figure 10A and Figure 10B Presented are data showing that anti-CD33 antibody variants of the present disclosure bind to human CD33 protein and cynomolgus CD33 protein, respectively.

[0145] Figure 11 Presented are data showing that anti-CD33 antibody variants of the present disclosure reduce cell surface levels of CD33 in primary human dendritic cells.

[0146] Figure 12A 、 Figure 12B and Figure 12C Presented are data showing that anti-CD33 antibody variants with Fc variants reduce cell surface levels of CD33 in primary human dendritic cells. DETAILED DESCRIPTION

[0147] The present disclosure relates to anti-CD33 antibodies (e.g., monoclonal antibodies); methods of making and using such antibodies; pharmaceutical compositions comprising such antibodies; nucleic acids encoding such antibodies; and host cells comprising nucleic acids encoding such antibodies.

[0148] The techniques and procedures described or referenced herein are generally well understood and are routinely employed by those skilled in the art using conventional methods, e.g., widely used methods such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual 3rd ed. (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Current Protocols in Molecular Biology (FM Ausubel et al., eds., (2003); Monoclonal Antibodies: A Practical Approach (P. Shepherd and C. Dean, eds., Oxford University Press, 2000).

[0149] I. Definition

[0150] Unless otherwise indicated, the terms "CD33" or "CD33 polypeptide" are used interchangeably herein to refer to any native CD33 from any vertebrate source, including mammals such as primates (e.g., humans and cynomolgus monkeys) and rodents (e.g., mice and rats). In some embodiments, the terms encompass wild-type sequences and naturally occurring variant sequences, such as splice variants or allelic variants. In some embodiments, the terms encompass "full-length," unprocessed CD33, as well as any form of CD33 produced by processing in cells. In some embodiments, CD33 is human CD33 isoform 1 (NCBI Reference Sequence: NP_001763.3). In some embodiments, the amino acid sequence of an exemplary human CD33 is SEQ ID NO: 1. The amino acid sequence of cynomolgus monkey CD33 is SEQ ID NO: 2 (NCBI Reference Sequence: XP_005590138.1).

[0151] The terms "anti-CD33 antibody," "antibody that binds to CD33," and "antibody that specifically binds to CD33" refer to an antibody that binds to CD33 with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent targeting CD33. In one embodiment, the extent of binding of the anti-CD33 antibody to an unrelated, non-CD33 polypeptide is less than about 10% of the binding of the antibody to CD33, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, the antibody that binds to CD33 has a specific affinity of <1 μM, <100 nM, <10 nM, <1 nM, <0.1 nM, <0.01 nM, or <0.001 nM (e.g., 10 -8 M or smaller, such as 10-8 M to 10 -13 M, for example, 10 -9 M to 10 -13 In certain embodiments, the anti-CD33 antibody binds to an epitope of CD33 that is conserved among CD33 from different species.

[0152] With respect to the binding of an antibody to a target molecule, the term "specific binding" or "specifically binds to" or "has specificity for" a particular polypeptide or an epitope on a particular polypeptide target means binding that is clearly distinct from non-specific interactions. For example, specific binding can be measured by determining the binding of a molecule compared to the binding of a control molecule. For example, specific binding can be determined by competition with a control molecule that is similar to the target (e.g., an excess of unlabeled target). In this case, if the binding of the labeled target to the probe is competitively inhibited by an excess of unlabeled target, specific binding is indicated. As used herein, the term "specifically binds to" a particular polypeptide or an epitope on a particular polypeptide target or "specifically binds to" or "has specificity for" a particular polypeptide or an epitope on a particular polypeptide target can be manifested, for example, by a molecule that has 10 -4 M or lower, 10 -5 M or lower, 10 -6 M or lower, 10 -7 M or lower, 10 -8 M or lower, 10 -9 M or lower, 10 -10 M or lower, 10 -11 M or lower, 10 -12 M or lower, or in the KD of 10 -4 M to 10 -6 M or 10 -6 M to 10 -10 M or 10 -7 M to 10 -9 As will be appreciated by those skilled in the art, affinity and KD values ​​are inversely correlated. High affinity for an antigen is measured by a low KD value. In one embodiment, the term "specific binding" refers to binding in which a molecule binds to a specific polypeptide or epitope on a specific polypeptide without substantially binding to any other polypeptide or polypeptide epitope.

[0153] The term "immunoglobulin" (Ig) is used interchangeably herein with "antibody." The term "antibody" is used herein in the broadest sense and specifically encompasses monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), including those formed from at least two intact antibodies, and antibody fragments, so long as they exhibit the desired biological activity.

[0154] "Native antibodies" are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light ("L") chains and two identical heavy ("H") chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has a variable domain (V H ), followed by many constant domains. Each light chain has a variable domain (V L ), with a constant domain at one end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. Specific amino acid residues are believed to form an interface between the light and heavy chain variable domains.

[0155] For the structure and properties of different classes of antibodies, see, e.g., Basic and Clinical Immunology, 8th ed., Daniel P. Stites, Abba I. Terr and Tristram G. Parslow (eds.), Appleton & Lange, Norwalk, CT, 1994, p. 71 and Chapter 6.

[0156] The light chains from any vertebrate species can be designated as two distinct types, kappa ("κ") and lambda ("λ"), based on the amino acid sequence of their constant domains. Immunoglobulins can be divided into different classes or isotypes based on the amino acid sequence of their heavy chain constant domains (CH). There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, which have heavy chains designated alpha ("α"), delta ("δ"), epsilon ("ε"), gamma ("γ"), and mu ("μ"), respectively. The gamma and alpha classes are further divided into subclasses (isotypes) based on relatively minor differences in CH sequence and function; for example, humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The subunit structures and three-dimensional configurations of the different classes of immunoglobulins are well known and generally described in, for example, Abbas et al. Cellular and Molecular Immunology, 4th edition (WB Saunders Co., 2000).

[0157] The "variable region" or "variable domain" of an antibody, such as an anti-CD33 antibody of the present disclosure, refers to the amino-terminal domain of the heavy or light chain of the antibody. The variable domains of the heavy and light chains may be referred to as "V H ” and “V L These domains are generally the most variable parts of an antibody (relative to other antibodies of the same class) and contain the antigen-binding site.

[0158] The term "variable" refers to the fact that certain segments of the variable domain differ greatly in sequence between antibodies (such as the anti-CD33 antibodies of the present disclosure). The variable domain mediates antigen binding and determines the specificity of a particular antibody for its specific antigen. However, variability is not evenly distributed across the entire span of the variable domain. Instead, it is concentrated in three segments called hypervariable regions (HVRs) in the light and heavy chain variable domains. The more highly conserved portions of the variable domain are called framework regions (FRs). The variable domains of native heavy and light chains each contain four FR regions that primarily adopt a β-sheet configuration connected by three HVRs, which form loops connecting, and in some cases form part of, the β-sheet structure. The HVRs in each chain are held together tightly by the FR regions and, together with the HVRs from the other chain, contribute to the formation of the antibody's antigen-binding site (see Kabat et al., Sequences of Immunological Interest, 5th ed., National Institute of Health, Bethesda, MD (1991)). The constant domains are not directly involved in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.

[0159] As used herein, the term "monoclonal antibody" refers to an antibody, such as the anti-CD33 monoclonal antibodies of the present disclosure, obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation, etc.), which may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by hybridoma cultures and are not contaminated by other immunoglobulins. The modifier "monoclonal" indicates the characteristic of the antibody as being obtained from a substantially homogeneous population of antibodies and should not be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies for use in accordance with the present disclosure can be prepared by a variety of techniques, including, but not limited to, one or more of the following methods: methods of immunizing animals (including, but not limited to, rats, mice, rabbits, guinea pigs, hamsters, and / or chickens) with one or more of one or more DNAs, virus-like particles, one or more polypeptides, and / or one or more cells, hybridoma methods, B cell cloning methods, recombinant DNA methods, and techniques for producing human or human-like antibodies in animals that have part or all of the human immunoglobulin loci or genes encoding human immunoglobulin sequences.

[0160] The terms "full-length antibody," "intact antibody," or "complete antibody" are used interchangeably to refer to an antibody, such as the anti-CD33 antibodies of the present disclosure, in its substantially intact form, as opposed to an antibody fragment. Specifically, complete antibodies include those having heavy and light chains that include an Fc region. The constant domains may be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variants thereof. In some cases, an intact antibody may have one or more effector functions.

[0161] "Antibody fragment" refers to a molecule other than an intact antibody that includes a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies (see U.S. Patent 5,641,870, Example 2; Zapata et al., Protein Eng. 8(10):1057-1062 (1995)); single-chain antibody molecules formed from antibody fragments; and multispecific antibodies.

[0162] Papain digestion of antibodies, such as the anti-CD33 antibodies of the present disclosure, produces two identical antigen-binding fragments, termed "Fab" fragments, and a residual "Fc" fragment, a name reflecting the ability to crystallize readily. The Fab fragment consists of the entire light chain and the variable region domain (V H ) and the first constant domain of a heavy chain (C H 1) Composition. Each Fab fragment is monovalent with respect to antigen binding, i.e., it has only a single antigen binding site. Pepsin treatment of an antibody produces a single large F(ab')2 fragment that roughly corresponds to two disulfide-linked Fab fragments, has different antigen binding activities, and is still able to cross-link antigen. Fab' fragments differ from Fab fragments in that they have a C H The carboxyl terminus of the constant domain has a few additional residues, including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which one or more cysteine ​​residues of the constant domains bear a free thiol group. F(ab')2 antibody fragments were originally produced as pairs of Fab' fragments that have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

[0163] The Fc fragment comprises the carboxyl-terminal portions of two heavy chains held together by disulfide bonds.The effector functions of an antibody are determined by sequences in the Fc region, which is also recognized by Fc receptors (FcR) on certain cell types.

[0164] "Functional fragments" of antibodies, such as the anti-CD33 antibodies of the present disclosure, comprise a portion of an intact antibody, generally including the antigen-binding or variable region of the intact antibody, or the Fc region of an antibody that retains or has modified FcR binding ability. Examples of antibody fragments include linear antibodies, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments.

[0165] The term "diabody" refers to a H With V L Small antibody fragments are prepared by using sFv fragments (see previous paragraph) with short linkers (about 5-10 residues) between the domains (enabling interchain, rather than intrachain, pairing of the variable domains, resulting in bivalent fragments, i.e., fragments with two antigen-binding sites). Bispecific diabodies are heterodimers of two "crossover" sFv fragments, in which the V domains of the two antibodies are bound to each other. H and V L Domains are present on different polypeptide chains.

[0166] As used herein, "chimeric antibody" refers to an antibody (immunoglobulin) in which a portion of the heavy chain and / or light chain is identical or homologous to the corresponding sequence in an antibody derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of one or more chains is identical or homologous to the corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass, such as the chimeric anti-CD33 antibodies of the present disclosure, as well as fragments of such antibodies, as long as they exhibit the desired biological activity. The chimeric antibodies of interest herein include An antibody wherein the antigen binding region of the antibody is derived from an antibody produced by, for example, immunizing a macaque with the antigen of interest. As used herein, "humanized antibodies" are a subgroup of "chimeric antibodies."

[0167] "Humanized" forms of non-human (e.g., murine) antibodies, such as humanized forms of the anti-CD33 antibodies of the present disclosure, are chimeric antibodies comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one (usually two) variable domains, wherein all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, such as a non-human antibody, refers to an antibody that has undergone humanization.

[0168] "Human antibody" refers to an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by a human and / or prepared using any of the techniques disclosed herein for preparing human antibodies, such as the anti-CD33 antibodies of the present disclosure. This definition of a human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues. Human antibodies can be produced using various techniques known in the art, including phage display libraries and yeast display libraries. Human antibodies can be prepared by administering an antigen to a transgenic animal that has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled, and produced by human B-cell hybridoma technology.

[0169] As used herein, the terms "hypervariable region," "HVR," or "HV" refer to regions of an antibody variable domain, such as those of the anti-CD33 antibodies of the present disclosure, that are hypervariable in sequence and / or form structurally defined loops. Generally, antibodies comprise six HVRs; three in the V H In (H1, H2, H3), three in V LIn natural antibodies, H3 and L3 show the greatest diversity of the six HVRs, and H3 in particular is thought to play a unique role in conferring fine specificity on antibodies. Naturally occurring camelid antibodies composed solely of heavy chains are functional and stable in the absence of light chains.

[0170] Many HVR descriptions are in use and are included in this article. In some embodiments, based on sequence variability, HVR can be a Kabat complementary determining region (CDR), and is the most commonly used (Kabat et al., supra). In some embodiments, HVR can be a Chothia CDR. And Chothia refers to the position of the structural loop (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)). In some embodiments, HVR can be an AbM HVR. AbM HVR represents a compromise between Kabat CDR and Chothia structural loops and is used by Oxford Molecular's AbM antibody modeling software. In some embodiments, HVR can be a "contact" HVR. "Contact" HVR is based on the analysis of available complex crystal structures. The residues from each of these HVRs are shown below.

[0171]

[0172]

[0173] An HVR may comprise an "extended HVR" as follows: 24-36 or 24-34 (L1), 46-56 or 50-56 (L2), and 89-97 or 89-96 (L3) in VL, and 26-35 (H1), 50-65 or 49-65 (preferred embodiment) (H2), and 93-102, 94-102, or 95-102 (H3) in VH. For each of these extended HVR definitions, the variable domain residues are numbered according to Kabat et al., supra.

[0174] "Framework" or "FR" residues are variable domain residues other than the HVR residues as herein defined.

[0175] As used herein, an "acceptor human framework" is an immunoglobulin framework comprising a V L or V HThe acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may comprise pre-existing amino acid sequence changes. In some embodiments, the number of pre-existing amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. When pre-existing amino acid changes are present in VH, preferably these changes occur only at three, two or one of positions 71H, 73H and 78H; for example, the amino acid residues at these positions may be 71A, 73T and / or 78A. In one embodiment, the VL acceptor human framework is identical in sequence to the V L The human immunoglobulin framework sequences or human consensus framework sequences are identical.

[0176] "Human consensus framework" represents the human immunoglobulin V L or V H The framework sequence is selected based on the most common amino acid residues. L or V H The sequence is selected from a subset of variable domain sequences. Generally, the subset of sequences is as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991). For example, for V L , the subgroup may be a kappa I, kappa II, kappa III, or kappa IV subgroup as in Kabat et al. (supra). H , the subgroup can be subgroup I, subgroup II or subgroup III as in Kabat et al., (supra).

[0177] An "amino acid modification" at a designated position of, for example, an anti-CD33 antibody of the present disclosure refers to a substitution or deletion of the designated residue, or an insertion of at least one amino acid residue adjacent to the designated residue. An insertion "adjacent" to a designated residue means an insertion within one to two residues thereof. The insertion may be at the N-terminus or C-terminus of the designated residue. Preferred amino acid modifications herein are substitutions.

[0178] "Affinity matured" antibodies, such as the affinity matured anti-CD33 antibodies of the present disclosure, are antibodies with one or more alterations in one or more of their HVRs that result in an increase in the affinity of the antibody for the antigen compared to a parent antibody that does not have those alterations. In one embodiment, affinity matured antibodies have nanomolar or even picomolar affinities for the target antigen. Affinity matured antibodies are produced by methods known in the art. For example, Marks et al. Bio / Technology 10:779-783 (1992) describe affinity matured antibodies produced by V H - and V L -Affinity maturation by domain shuffling. Random mutagenesis of HVR and / or framework residues is described, for example, by: Barbas et al., Proc Nat. Acad. Sci. USA 91:3809-3813 (1994); Schier et al., Gene 169:147-155 (1995); Yelton et al., J. Immunol. 155:1994-2004 (1995); Jackson et al., J. Immunol. 154(7):3310-9 (1995); and Hawkins et al., J. Mol. Biol. 226:889-896 (1992).

[0179] "Fv" is the smallest antibody fragment that contains a complete antigen recognition and binding site. This fragment consists of a tight, non-covalently associated dimer of a heavy chain variable region domain and a light chain variable region domain. Six hypervariable loops (3 loops each from the H and L chains) are generated from the folding of these two domains, which provide amino acid residues for antigen binding and give the antibody antigen binding specificity. However, even a single variable domain (or half of an Fv containing only three HVRs specific for an antigen) has the ability to recognize and bind to an antigen, although the affinity is lower than that of the complete binding site.

[0180] "Single-chain Fv" (also abbreviated as "sFv" or "scFv") is an antibody fragment comprising the VH and VL antibody domains linked into a single polypeptide chain. Preferably, the sFv polypeptide also comprises a VH domain and a VL domain. H With V L A polypeptide linker between the domains enables the sFv to form the desired structure for antigen binding.

[0181] Antibody "effector functions" refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody, and vary with the antibody isotype.

[0182] The term "Fc region" is used herein to define the C-terminal region of an immunoglobulin heavy chain, including native sequence Fc regions and variant Fc regions. Although the boundaries of the Fc regions of immunoglobulin heavy chains may be different, the human IgG heavy chain Fc region is generally defined as extending from the amino acid residue at position Cys226 or from Pro230 to its carboxyl terminus. For example, in the production or purification process of an antibody, or by recombinant engineering of nucleic acids encoding an antibody heavy chain, the C-terminal lysine (residue 447 according to the EU numbering system) in the Fc region can be removed. Therefore, the composition of a complete antibody can include antibody groups that have all K447 residues removed, antibody groups that do not remove the K447 residue, and antibody groups with and without a mixture of antibodies containing the K447 residue. Suitable native sequence Fc regions for antibodies of the present disclosure include human IgG1, IgG2, IgG3, and IgG4.

[0183] A "native sequence Fc region" comprises an amino acid sequence identical to the amino acid sequence of an Fc region found in nature. Native sequence human Fc regions include native sequence human IgG1 Fc regions (non-A and A allotypes); native sequence human IgG2 Fc regions; native sequence human IgG3 Fc regions; and native sequence human IgG4 Fc regions and naturally occurring variants thereof.

[0184] A "variant Fc region" comprises an amino acid sequence that differs from the amino acid sequence of a native sequence Fc region by at least one amino acid modification, preferably one or more amino acid substitutions. Preferably, the variant Fc region has at least one amino acid substitution, e.g., from about 1 to about 10 amino acid substitutions, preferably from about 1 to about 5 amino acid substitutions, compared to the native sequence Fc region or the Fc region of a parent polypeptide. The variant Fc region herein will preferably have at least about 80% homology to the native sequence Fc region and / or the Fc region of the parent polypeptide, and most preferably at least about 90% homology thereto, more preferably at least about 95% homology thereto.

[0185] "Fc receptor" or "FcR" describes a receptor that binds to the Fc region of an antibody. A preferred FcR is a native sequence human FcR. In addition, a preferred FcR is an FcR that binds to IgG antibodies (gamma receptors), including receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternative splicing forms of these receptors, FcγRII receptors including FcγRIIA ("activating receptor") and FcγRIIB ("inhibitory receptor"), which have similar amino acid sequences, differing primarily in their cytoplasmic domains. The activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif ("ITAM") in its cytoplasmic domain. The inhibitory receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif ("ITIM") in its cytoplasmic domain. The term "FcR" herein encompasses other FcRs, including those to be identified in the future. FcRs can also extend the serum half-life of antibodies.

[0186] As used herein, "percent (%) amino acid sequence identity" and "homology" with respect to peptide, polypeptide or antibody sequences refers to the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a particular peptide or polypeptide sequence, after aligning the sequences and introducing gaps (if necessary) to achieve the maximum percentage of sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for the purpose of determining percent amino acid sequence identity can be performed in various ways within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or MEGALIGN. TM (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms known in the art needed to achieve maximal alignment over the full length of the sequences being compared.

[0187] The term "compete" when used in the context of antibodies that compete for the same epitope (e.g., neutralizing antibodies) refers to competition between antibodies as determined by an assay in which the antibody being tested prevents or inhibits (e.g., reduces) specific binding of a reference molecule (e.g., a ligand or reference antibody) to a common antigen (e.g., CD33 or a fragment thereof). Many types of competitive binding assays can be used to determine whether an antibody competes with another antibody, e.g., solid phase direct or indirect radioimmunoassays (RIA), solid phase direct or indirect enzyme immunoassays (EIA), sandwich competition assays (see, e.g., Stahli et al., 1983, Methods in Enzymology 9:242-253); solid phase direct biotin-avidin EIA (see, e.g., Kirkland et al., 1986, J. Immunol. 137:3614-3619), solid phase direct label assays, solid phase direct label sandwich assays (see, e.g., Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1992). Press); solid phase direct label RIA using I-125 labels (see, e.g., Morel et al., 1988, Molec. Immunol. 25: 7-15); solid phase direct biotin-avidin EIA (see, e.g., Cheung et al., 1990, Virology 176: 546-552); and direct label RIA (Moldenhauer et al., 1990, Scand. J. Immunol. 32: 77-82). Typically, such assays involve the use of purified antigen bound to a solid surface or cell carrying either an unlabeled test antibody or a labeled reference antibody. Competitive inhibition is measured by measuring the amount of label bound to the solid surface or cell in the presence of the test antibody. Typically, the test antibody is present in excess. Antibodies identified by competitive assays (competing antibodies) include antibodies that bind to the same epitope as the reference antibody and antibodies that bind to an adjacent epitope that is sufficiently close to the epitope bound by the reference antibody to cause steric hindrance. This article provides additional details about the method for determining competitive binding. Typically, when the competing antibody is present in excess, it will inhibit (e.g., reduce) the specific binding of the reference antibody to the common antigen by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 97.5% and / or approach 100%.

[0188] As used herein, an "interaction" between a CD33 polypeptide and a second polypeptide includes, but is not limited to, protein-protein interactions, physical interactions, chemical interactions, binding, covalent binding, and ionic binding. As used herein, an antibody "inhibits an interaction between two polypeptides" when it disrupts, reduces, or completely eliminates the interaction between the two polypeptides. When an antibody of the present disclosure binds to one of the two polypeptides, it thereby "inhibits an interaction between the two polypeptides." In some embodiments, the interaction may be inhibited by at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 97.5%, and / or approaching 100%.

[0189] The term "epitope" includes any determinant capable of being bound by an antibody. An epitope is a region of an antigen that is bound by an antibody targeting that antigen, and when the antigen is a polypeptide, the epitope includes specific amino acids that directly contact the antibody. In most cases, epitopes are found on polypeptides, but in some cases, they may be found on other types of molecules such as nucleic acids. Epitope determinants may include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and may have specific three-dimensional structural characteristics and / or specific charge characteristics. Typically, an antibody specific for a particular target antigen will preferentially recognize an epitope on the target antigen in a complex mixture of polypeptides and / or macromolecules.

[0190] An "agonistic" antibody or "activating" antibody is an antibody that, upon binding of the antigen, induces (eg, enhances) one or more activities or functions of the antigen.

[0191] An "antagonist" antibody or "blocking" antibody or "inhibitory" antibody is an antibody that reduces, inhibits, and / or eliminates (e.g., reduces) the binding of an antigen to one or more ligands after the antibody binds to the antigen, and / or reduces, inhibits, and / or eliminates (e.g., attenuates) one or more activities or functions of the antigen after the antibody binds to the antigen. In some embodiments, an antagonist, blocking, or inhibitory antibody substantially or completely inhibits the binding of the antigen to one or more ligands and / or one or more activities or functions of the antigen.

[0192] An "isolated" antibody, such as an isolated anti-CD33 antibody of the present disclosure, is one that has been identified, separated, and / or recovered (e.g., naturally or recombinantly) from a component of the environment in which it is produced. Preferably, an isolated antibody is free from association with all other contaminating components of the environment in which it is produced. Contaminating components of the environment in which it is produced, such as those produced by recombinant transfected cells, are substances that would normally interfere with the research, diagnostic, or therapeutic use of the antibody and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the antibody is purified: (1) to greater than 95% by weight of the antibody as determined by, for example, the Lowry method, and in some embodiments, to greater than 99% by weight; (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence using a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie Brilliant Blue or, preferably, silver stain. An isolated antibody includes the antibody in situ within a recombinant T cell, since at least one component of the antibody's natural environment will be absent. Ordinarily, however, isolated polypeptide or antibody will be prepared by at least one purification step.

[0193] An "isolated" nucleic acid molecule encoding an antibody, such as an anti-CD33 antibody of the present disclosure, is one that has been identified and separated from at least one contaminating nucleic acid molecule with which it is normally associated in the environment in which it is produced. Preferably, the isolated nucleic acid is free from all components associated with the environment in which it is produced. An isolated nucleic acid molecule encoding the polypeptides and antibodies herein is in a form that is different from the form or context in which it is found in nature. Thus, an isolated nucleic acid molecule is distinct from nucleic acids encoding the polypeptides and antibodies herein that are naturally present in cells.

[0194] As used herein, the term "vector" is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid connected thereto. One type of vector is a "plasmid," which refers to a circular double-stranded DNA to which another DNA segment can be connected. Another type of vector is a bacteriophage vector. Another type of vector is a viral vector, in which another DNA segment can be connected to the viral genome. Some vectors can replicate autonomously in the host cell into which they are introduced (e.g., bacterial vectors and episomal mammalian vectors with bacterial replication origins). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of the host cell after being introduced into the host cell, thereby replicating together with the host genome. In addition, some vectors can guide the expression of the gene operably connected thereto. Such vectors are referred to herein as "recombinant expression vectors," or simply as "expression vectors." Typically, expression vectors useful in recombinant DNA technology exist in the form of plasmids. In this specification, "plasmid" and "vector" can be used interchangeably because plasmids are the most commonly used vector forms.

[0195] "Polynucleotide" or "nucleic acid," as used interchangeably herein, refers to polymers of nucleotides of any length and includes DNA and RNA. The nucleotides may be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and / or analogs thereof, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase or by a synthetic reaction.

[0196] "Host cell" includes a single cell or cell culture that can be or has been a recipient of one or more vectors for incorporating a polynucleotide insert. Host cells include the progeny of a single host cell, and due to natural, accidental, or deliberate mutation, the progeny may not necessarily be completely identical (in morphology or genomic DNA complement) to the original parent cell. Host cells include cells transfected in vivo with one or more polynucleotides of the present disclosure.

[0197] As used herein, "carrier" includes pharmaceutically acceptable carriers, excipients, or stabilizers that are non-toxic to cells or mammals exposed thereto at the dosages and concentrations employed.

[0198] As used herein, the term "preventing" includes providing protection against the occurrence or recurrence of a particular disease, condition, or disorder in an individual. An individual may be predisposed to, susceptible to, or at risk of developing a particular disease, condition, or disorder but has not yet been diagnosed with the disease, condition, or disorder.

[0199] As used herein, an individual who is "at risk" for developing a particular disease, condition, or disorder may or may not have detectable disease or disease symptoms, and may or may not have displayed detectable disease or disease symptoms prior to the treatment methods described herein. "At risk" means that an individual has one or more risk factors, which are measurable parameters associated with the development of a particular disease, condition, or disorder, as known in the art. An individual who has one or more of these risk factors has a higher probability of developing a particular disease, condition, or disorder than an individual who does not have one or more of these risk factors.

[0200] As used herein, the term "treatment" refers to a clinical intervention designed to alter the natural course of a disease in a treated individual during the course of clinical pathology. Desirable effects of treatment include reducing the rate of progression, ameliorating or lessening the pathological state, alleviating the specific disease, condition, or disorder, or improving its prognosis. For example, a subject is successfully "treated" if one or more symptoms associated with a specific disease, condition, or disorder are alleviated or eliminated.

[0201] "Effective amount" refers to at least an effective amount that achieves the desired therapeutic or preventive result at the desired dosage and time period. The effective amount can be provided in one or more administrations. The effective amount herein can vary according to factors such as the individual's disease state, age, sex, and weight, as well as the ability of the treatment to elicit the desired response in the individual. An effective amount is also an amount in which any toxic or harmful effects of the treatment are outweighed by the beneficial effects of the treatment. For prophylactic use, beneficial or desired results include results such as eliminating or reducing risk, reducing severity, or delaying the onset of a disease (including biochemical, histological, and / or behavioral symptoms of the disease, its complications, and intermediate pathological phenotypes that occur during the course of disease progression). For therapeutic use, beneficial or desired results include clinical results, such as reducing one or more symptoms caused by the disease, improving the quality of life of those suffering from the disease, reducing the dose of other drugs required to treat the disease, enhancing the effect of another drug (such as through targeting), delaying the progression of the disease, and / or prolonging life. The effective amount of a drug, compound, or pharmaceutical composition is an amount sufficient to directly or indirectly achieve a preventive or therapeutic treatment. As understood in a clinical context, an effective amount of a drug, compound, or pharmaceutical composition may or may not be combined with another drug, compound, or pharmaceutical composition. Thus, an "effective amount" may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be provided in an effective amount if, in combination with one or more other agents, the desired result can be achieved or achieved.

[0202] A "subject" for purposes of treatment, prevention, or risk reduction refers to any animal classified as a mammal, including humans, livestock and farm animals, and zoo, sport, or pet animals, such as dogs, horses, rabbits, cows, pigs, hamsters, gerbils, mice, ferrets, rats, cats, etc. In some embodiments, the subject is a human.

[0203] As used herein, administration "in conjunction with" another compound or composition includes simultaneous administration and / or administration at different times. Administration in conjunction also includes administration as a co-formulation or as separate compositions, including administration at different dosing frequencies or intervals, and administration using the same route of administration or different routes of administration. In some embodiments, administration in conjunction is administration as part of the same treatment regimen.

[0204] As used herein, the term "about" refers to the typical error range of each value that is readily known to those skilled in the art. "About" values ​​or parameters mentioned herein include (and describe) embodiments for the value or parameter itself.

[0205] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. For example, reference to an "antibody" is a reference to one to multiple antibodies (such as molar amounts) and includes equivalents thereof known to those skilled in the art, and so forth.

[0206] It should be understood that aspects and embodiments of the present disclosure described herein include "comprising" aspects and embodiments, "consisting of" aspects and embodiments, and "consisting essentially of" aspects and embodiments.

[0207] Overview

[0208] The present disclosure relates, in part, to anti-CD33 antibodies that exhibit one or more improved and / or enhanced functional characteristics (e.g., relative to an anti-CD33 antibody having a heavy chain variable region comprising the sequence of SEQ ID NO: 3 and a light chain variable region comprising the sequence of SEQ ID NO: 4), including, for example, antibodies that are capable of reducing cell surface levels of CD33 and / or binding to CD33 with improved / enhanced kinetics; methods of making and using such antibodies; pharmaceutical compositions containing such antibodies; nucleic acids encoding such antibodies; and host cells containing nucleic acids encoding such antibodies.

[0209] In some embodiments, the anti-CD33 antibodies of the present disclosure have one or more activities that are attributable, at least in part, to the ability of the antibodies to inhibit the interaction between CD33 and one or more natural glycan ligands. In some embodiments, the anti-CD33 antibodies of the present disclosure may have one or more activities that are attributable, at least in part, to the ability of the antibodies to reduce cellular expression (e.g., cell surface expression) of CD33 by inducing degradation, downregulation, cleavage, receptor desensitization, and / or lysosomal targeting of CD33. In some embodiments, the anti-CD33 antibodies exhibit one or more of the following properties: a) having a dissociation constant (K) for human CD33 that is lower than the dissociation constant of an anti-CD33 antibody having a heavy chain variable region comprising the sequence of SEQ ID NO: 3 and a light chain variable region comprising the sequence of SEQ ID NO: 4; D ); b) binds to human cells, such as primary human dendritic cells; c) at a half-maximal effective concentration (EC) of an anti-CD33 antibody having a heavy chain variable region comprising the sequence of SEQ ID NO: 3 and a light chain variable region comprising the sequence of SEQ ID NO: 4. 50 ) half-maximal effective concentration (EC 50 ) reduces the cell surface level of CD33 (e.g., reduces the cell surface level of CD33 on primary human dendritic cells in vitro); d) has a dissociation constant (K) for human CD33 that can be in the range of about 0.061 nM to about 0.40 nMD ), for example, when K D as measured by surface plasmon resonance or biofilm interferometry; and / or e. reducing cell surface levels of CD33 (e.g., reducing cell surface levels of CD33 on primary human dendritic cells in vitro), where the half-maximal effective concentration (EC 50 ) can be in the range of about 78 pM to about 40 pM, for example when EC is measured in vitro by flow cytometry. 50 As disclosed herein, the half-maximal effective concentration (EC 50 ) refers to the concentration of an anti-CD33 antibody of the present disclosure that reduces the cellular level of CD33 on or in a cell to half the cellular level of CD33 of untreated cells, or the concentration at which the antibody achieves half-maximal binding to CD33 on a cell.

[0210] Advantageously, the anti-CD33 antibodies of the present disclosure are more efficient (e.g., with a lower EC ) than a control anti-CD33 antibody (e.g., a control anti-CD33 antibody having a heavy chain variable region comprising the sequence of SEQ ID NO: 3 and a light chain variable region comprising the sequence of SEQ ID NO: 4). 50 ) reduces cell surface expression of CD33 (e.g., up to about 1.6-fold or up to 18-fold) (see, e.g., Example 3). Furthermore, advantageously, the anti-CD33 antibodies of the present disclosure have a higher affinity (e.g., up to about 7-fold higher affinity) for CD33 compared to a control anti-CD33 antibody (e.g., a control anti-CD33 antibody having a heavy chain variable region comprising the sequence of SEQ ID NO: 3 and a light chain variable region comprising the sequence of SEQ ID NO: 4) (e.g., a lower K as measured by surface plasmon resonance). D Surprisingly, higher affinity for CD33 did not necessarily correlate with increased ability to reduce cell surface expression of CD33 or efficacy.

[0211] Certain aspects of the present disclosure are based, at least in part, on the identification of anti-CD33 antibodies or one or more chemotherapeutic agents and / or various cancer vaccines that exhibit one or more improved and / or enhanced functional characteristics (e.g., relative to an anti-CD33 antibody having a heavy chain variable region comprising the sequence of SEQ ID NO: 3 and a light chain variable region comprising SEQ ID NO: 4), including an improved / enhanced ability to reduce the level of cellular expression of CD33 on a cell, thereby resulting in reduction, neutralization, prevention or inhibition of one or more CD33 activities, including, but not limited to, reducing cell growth of monocytes, macrophages, T cells, dendritic cells and / or microglia; reducing cell proliferation of dendritic cells, bone marrow-derived dendritic cells, monocytes, microglia, M1 microglia, activated M1 microglia, M2 microglia, macrophages, M1 macrophages, M2 microglia, M2 macrophages ... induced by neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia and / or M2 microglia; reduce the survival of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, The drug inhibits the proliferation of monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia; inhibits the migration of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia; reduces the cells, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia; reduce the proliferation of monocytes, macrophages, T cells, dendritic cells, neutrophils, and / or microglia; reduce the overall function of monocytes, macrophages, T cells, dendritic cells, neutrophils, and / or microglia;Suppressing beneficial immune responses to different types of cancer selected from bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin lymphoma, acute myeloid leukemia, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma and thyroid cancer; Suppressing beneficial immune responses to different types of neurological disorders selected from dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, Creutzfeldt-Jakob disease disease), normal pressure hydrocephalus, amyotrophic lateral sclerosis, Huntington's disease, tauopathy, Nasu-Hakola disease, stroke, acute trauma, chronic trauma, essential tremor, Behçet's disease, Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, Shy-Drager syndrome, progressive supranuclear palsy, corticobasal degeneration, acute disseminated encephalomyelitis, granulomatous disorders, sarcoidosis, diseases of aging, epilepsy, spinal cord injury, traumatic brain injury, age-related macular degeneration, glaucoma, retinitis pigmentosa, retinal degeneration, and multiple sclerosis. sclerosis; binds to CD33 ligands on tumor cells; binds to CD33 ligands on dendritic cells, bone marrow-derived dendritic cells, monocytes, microglia, T cells, neutrophils and / or macrophages; inhibits tumor cell killing by one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells or cytotoxic T cells; inhibits microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells or cytotoxic T cells T cells or cytotoxic T cells; inhibiting the anti-tumor cell proliferation activity of one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells or cytotoxic T cells; regulating the expression of one or more inflammatory receptors such as CD86 expressed on one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells or cytotoxic T cells; enhancing immunity Infiltration of one or more of suppressive dendritic cells, immunosuppressive macrophages, myeloid-derived suppressor cells, tumor-associated macrophages, immunosuppressive neutrophils, and regulatory T cells into tumors; increasing the number of tumor-promoting myeloid / granulocytic immunosuppressive cells in tumors, peripheral blood, or other lymphoid organs; enhancing the tumor-promoting activity of myeloid-derived suppressor cells; reducing the activation of tumor-specific T lymphocytes with tumor-killing potential; reducing the infiltration of tumor-specific T lymphocytes with tumor-killing potential; increasing the rate of tumor growth; increasing the rate of tumor recurrence;Reducing the efficacy of one or more immunotherapies that modulate anti-tumor T cell responses, optionally wherein the one or more immunotherapies are immunotherapies targeting one or more proteins selected from the group consisting of CD40, OX40, ICOS, CD28, CD137 / 4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7-H4, HVEM, LIGHT, BTLA, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR, LAG3, DR-5, CD39, CD70, TREM1, TREM2, Siglec-5, Siglec-7, Siglec-9, Siglec-11, SirpA, CD447, CSF-1 receptor, and any combination thereof;

[0212] In some embodiments, treating cancer with the anti-CD33 antibodies described herein can: (i) increase tumor infiltrating CD3 + (ii) decrease the number of non-tumorigenic CD14 + Cellular levels of CD33 in myeloid cells, optionally including non-tumorigenic CD14 + Myeloid cells are tumor infiltrating cells, or optionally non-tumorigenic CD14 + Myeloid cells are present in the blood; (iii) reduce non-tumorigenic CD14 + The number of myeloid cells, optionally including non-tumorigenic CD14 + Myeloid cells are tumor infiltrating cells, or optionally non-tumorigenic CD14 + myeloid cells present in the blood; (iv) reducing the level of PD-L1, PD-L2, B7-H7, B7-H3, CD200R, CD163 and / or CD206 in one or more cells, optionally wherein the one or more cells are non-tumorigenic myeloid-derived suppressor cells (MDSCs); (v) reducing the tumor growth rate of solid tumors; (vi) reducing tumor volume; (vii) improving the efficacy of one or more PD-1 inhibitors; (viii) improving the efficacy of one or more checkpoint inhibitor therapies and / or immunomodulatory therapies, optionally wherein the one or more checkpoint inhibitor therapies and / or immunomodulatory therapies target one or more of CTL4, adenosine pathway, PD-L1, PD-L2, OX40, TIM3, LAG3 or any combination thereof; (ix) improving the efficacy of one or more chemotherapeutic agents, optionally wherein the one or more chemotherapeutic agents are gemcitabine, capecitabine, anthracyclines, doxorubicin Epirubicin Taxanes, paclitaxel Docetaxel 5-fluorouracil (5-FU), cyclophosphamide Carboplatin and any combination thereof; (x) increasing the proliferation of T cells in the presence of non-tumorigenic myeloid-derived suppressor cells (MDSCs); (xi) inhibiting the differentiation, survival and / or one or more functions of non-tumorigenic myeloid-derived suppressor cells (MDSCs); and (xii) when conjugated to chemical or radioactive toxins, killing CD33-expressing immunosuppressant non-tumorigenic myeloid cells and / or non-tumorigenic CD14-expressing cells in solid tumors and associated blood vessels.

[0213] In some embodiments, the myeloid cells of the present disclosure include but are not limited to CD45+CD14+ myeloid cells, CD14+ myeloid cells and myeloid-derived suppressor cells (MDSC). In some embodiments, the myeloid cells of the present disclosure are non-tumorigenic myeloid cells. Immunosuppressive cells are sometimes also referred to as myeloid-derived suppressor cells (MDSC). In humans, MDSC can be defined by one of the following combinations of markers: (1) CD14+HLA-DRlow / -, (2) CD14+IL4Rα+, (3) CD14+HLA-DR-IL4Rα+, (4) CD34+CD14+CD11b+CD33+, (5) CD11b+CD14+CD33+, (6) CD33+HLA-DR-, (7) Lin-HLA-DR-, (8) Lin-HLA-DR-CD33+, (9) Lin-HLA-DR-CD33+C D11b+, (10)Lin-CD33+CD11b+CD15+, (11)Lin-HLA-DR-CD33+CD11b+CD14-CD15+, (12)CD11b+CD14-CD33+, (13)CD11b +CD14-HLA-DR-CD33+CD15+, (14)CD33+HLA-DR-CD15+, (15)CD15+IL4Rα+, (16)CD11b+CD15+CD66b+, (17)CD15+FSClow SSChigh, (18) CD15high CD33+, (19) CD11b+CD14-CD15+, (20) CD66b+SSChigh and (21) CD11b+CD15+ (see also Solito S et al. Annals of the NY Academy of Sciences, 2014). In mice, MDSCs can be defined by the expression of surface markers CD45+, CD11b+, Gr1+ and / or Il4Ra+. Other exemplary immunosuppressive monocyte lineages are CD45+, CD11b+, Gr1low; and CD45+, CD11c+.

[0214] CD33 protein

[0215] In one aspect, the present disclosure provides antibodies, such as isolated (e.g., monoclonal) antibodies, that interact with or otherwise bind to a region (e.g., an epitope) within a CD33 protein of the present disclosure. In some embodiments, the antibodies interact with or otherwise bind to a region (e.g., an epitope) within a CD33 protein of the present disclosure with improved / enhanced kinetics (e.g., relative to an anti-CD33 antibody having a heavy chain variable region comprising the sequence of SEQ ID NO: 3 and a light chain variable region comprising the sequence of SEQ ID NO: 4). In some embodiments, the antibodies interact with or otherwise bind to a region (e.g., an epitope) within a CD33 protein of the present disclosure at a lower half-maximal effective concentration (EC) than a control antibody (e.g., relative to an anti-CD33 antibody having a heavy chain variable region comprising the sequence of SEQ ID NO: 3 and a light chain variable region comprising the sequence of SEQ ID NO: 4). 50 ) interacts with or otherwise binds to a region (such as an epitope) within a CD33 protein on a human cell (such as a dendritic cell) at a half-maximal effective concentration of . In some embodiments, the anti-CD33 antibodies of the present disclosure bind to a CD33 protein and, upon binding to the CD33 protein, modulate one or more CD33 activities, for example, activities associated with CD33 expression on a cell. The CD33 proteins of the present disclosure include, but are not limited to, mammalian CD33 proteins, human CD33 proteins, mouse CD33 proteins, and rat CD33 proteins.

[0216] CD33 is variously referred to as CD33 molecule, Siglec3, Siglec-3, CD33 antigen (Gp67), P67, Gp67, sialic acid-binding-Ig-like lectin 3, myeloid cell surface antigen CD33, or FLJ00391.

[0217] CD33 is an immunoglobulin-like receptor expressed primarily on cells of the myeloid lineage (including but not limited to macrophages, dendritic cells, osteoclasts, monocytes, and microglia). In some embodiments, CD33 forms a receptor signaling complex with CD64. In some embodiments, CD33 signaling leads to downstream inhibition of PI3K or other intracellular signals. On myeloid cells, Toll-like receptor (TLR) signaling is important for inhibiting CD33 activity, for example, in the context of an infectious response. TLRs also play a key role in pathological inflammatory responses, such as those expressed on macrophages and dendritic cells.

[0218] The amino acid sequence of human CD33 is shown in SEQ ID NO: 1 below:

[0219] MPLLLLLPLLWAGALAMDPNFWLQVQESVTVQEGLCVLVPCTFFHPIPYYDKNSPVHGYWFREGAIISRDSPVATNKLDQEVQEETQGRFRLLGDPSRNNCSLSIVDARRRDNGSYFFRMERGSTKYSYKSPQLSVHVTDLTHRPKILIPGTLEPGHSKNLTCSVSWACEQGTPPIFSWLSAAPTSLGPRTTHSSVLIITPRPQDHGTNLTCQVKFAGAGVTTERTIQLNVTYVPQNPTTGIFPGDGSGKQETRAGVVHGAIGGAGVTALLALCLCLIFFIVKTHRRKAARTAVGRNDTHPTTGSASPKHQKKSKLHGPTETSSCSGAAPTVEMDEELHYASLNFHGMNPSKDTSTEYSEVRTQ

[0220] The amino acid sequence of cynomolgus macaque CD33 is shown in SEQ ID NO:2 below:

[0221] MDGEHLKGRNQGAQETSASDMPLLLLPLLWAGALAMDPRVRLEVQESVTVQEGLCVLVPCTFFHPVPYHTRNSPVHGYWFREGAIVSLDSPVATNKLDQEVQEETQGRFRLLGDPSRNNCSLSIVDARRRDNGSYFFRMEKGSTKYSYKSTQLSVHVTDLTHRPQILIPGALDPDHSKNLTCSVPWACEQGTPPIFSWMSAAPTSLGLRTTHSSVLIITPRPQDHGTNLTCQVKFPGAGVTTERTIQLNVSYASQNPRTDIFLGDGSGKQGVVQGAIGGAGVTVLLALCLCLIFFTVKTHRRKAARTAVGRIDTHPATGPTSSKHQKKSKLHGATETSGCSGTTLTVEMDEELHYASLNFHGMNPSEDTSTEYSEVRTQ

[0222] In some embodiments, CD33 is a proprotein comprising a signal sequence. In some embodiments, CD33 is a mature protein. In some embodiments, the mature CD33 protein does not include a signal sequence. In some embodiments, the mature CD33 protein is expressed on cells. In some embodiments, the mature CD33 protein is expressed on cells (such as cell surfaces), including but not limited to human dendritic cells, human macrophages, human monocytes, human osteoclasts, human neutrophils, human T cells, human helper T cells, human cytotoxic T cells, human granulocytes, and human microglia. The anti-CD33 antibodies of the present disclosure can bind to any CD33 protein of the present disclosure expressed on any cell disclosed herein.

[0223] The CD33 proteins of the present disclosure, such as human CD33, comprise several domains, including, but not limited to, a signal sequence located at amino acid residues 1-17 of SEQ ID NO: 1, an extracellular immunoglobulin-like variable (IgV) domain located at amino acid residues 19-135 of SEQ ID NO: 1, an Ig-like C2-type domain located at amino acid residues 145-228 of SEQ ID NO: 1, a transmembrane domain located at amino acid residues 260-282 of SEQ ID NO: 1, an ITIM motif 1 located at amino acid residues 338-343 of SEQ ID NO: 1, and an ITIM motif 2 located at amino acid residues 356-361 of SEQ ID NO: 1. As will be appreciated by those skilled in the art, the start and end residues of the domains of the present disclosure may vary depending on the computer modeling program used or the method used to determine the domains.

[0224] Certain aspects of the present disclosure provide anti-CD33 antibodies that bind to human CD33 or a homolog thereof, including but not limited to mammalian CD33 proteins and CD33 orthologs from other species. In some embodiments, the anti-CD33 antibodies of the present disclosure bind to human CD33 or a homolog thereof with improved / enhanced binding kinetics and / or improved activity, such as reducing cellular levels of CD33 (e.g., relative to an anti-CD33 antibody having a heavy chain variable region comprising the sequence of SEQ ID NO: 3 and a light chain variable region comprising the sequence of SEQ ID NO: 4).

[0225] Therefore, as used herein, the "CD33" protein of the present disclosure includes, but is not limited to, mammalian CD33 protein, human CD33 protein, primate CD33 protein, mouse CD33 protein, and rat CD33 protein. In addition, the anti-CD33 antibodies of the present disclosure can bind to epitopes in human CD33 protein and primate CD33. In some embodiments, the anti-CD33 antibodies of the present disclosure can specifically bind to human CD33. In some embodiments, the anti-CD33 antibodies of the present disclosure can bind to cynomolgus monkey CD33. In some embodiments, the anti-CD33 antibodies of the present disclosure can bind to both human CD33 and cynomolgus monkey CD33.

[0226] In some embodiments, the antibodies of the present disclosure can bind to CD33 in a pH-dependent manner. In some embodiments, the antibodies of the present disclosure can bind to CD33 at neutral pH and be internalized without dissociating from the CD33 protein. Alternatively, at acidic pH, once internalized, the antibodies of the present disclosure can dissociate from CD33 and then be degraded through the endosomal / lysosomal pathway. In certain embodiments, the anti-CD33 antibodies bind to CD33 at a pH in the range of 5.5 to 8.0, 5.5 to 7.5, 5.5 to 7.0, 5.5 to 6.5, 5.5 to 6.0, 6.0 to 8.0, 6.5 to 8.0, 7.0 to 8.0, 7.5 to 8.0, 6.0 to 7.5, 6.0 to 7.0, 6.5 to 7.5. In certain embodiments, the anti-CD33 antibody dissociates from CD33 at a pH of less than 6.0, less than 5.5, less than 5.0, less than 4.5, less than 4.0, less than 3.5, less than 3.0, less than 2.5, or less than 2.0.

[0227] In some embodiments, the antibodies of the present disclosure bind to a wild-type CD33 protein of the present disclosure, a naturally occurring variant thereof, and / or a disease variant thereof.

[0228] In some embodiments, the antibodies of the present disclosure bind to a variant of human CD33, wherein the variant comprises the single nucleotide polymorphism (SNP) rs3865444C having a (C) nucleotide. In some embodiments, the antibodies of the present disclosure that reduce the cellular level of CD33 and / or bind to or interact with CD33 bind to a variant of human CD33, wherein the variant comprises the SNP rs3865444 having a (A) nucleotide. In some embodiments, the anti-CD33 antibodies of the present disclosure bind to a variant of human CD33, wherein the variant comprises the SNP rs3865444 AC or rs3865444 CC .

[0229] In some embodiments, the antibodies of the present disclosure that reduce the cellular level of CD33 and / or bind to or interact with CD33 bind to a variant of human CD33, wherein the variant comprises SNP rs35112940 having a GG nucleotide, an AA nucleotide, or an AG nucleotide. In some embodiments, the antibodies of the present disclosure that reduce the cellular level of CD33 and / or bind to or interact with CD33 bind to a variant of human CD33, wherein the variant comprises SNP rs12459419 having a CC, CT, or TT genotype. In certain embodiments, the subject is homozygous or heterozygous for the coding SNP (rs1803 having a GG nucleotide, a CG nucleotide, or a CC nucleotide).

[0230] In some embodiments, the antibodies of the present disclosure that reduce the cellular level of CD33 and / or bind to or interact with CD33 bind to CD33 proteins expressed on the surface of cells, including but not limited to human dendritic cells, human macrophages, human monocytes, human osteoclasts, human neutrophils, human T cells, human T helper cells, human cytotoxic T cells, human granulocytes, and human microglial cells. In some embodiments, the antibodies of the present disclosure that reduce the cellular level of CD33 and / or bind to or interact with CD33 bind to CD33 proteins expressed on the surface of cells and, after binding to surface-expressed CD33 proteins, modulate (e.g., induce or inhibit) at least one CD33 activity of the present disclosure. In some embodiments of the present disclosure, anti-CD33 antibodies specifically bind to CD33 proteins. In some embodiments of the present disclosure, anti-CD33 antibodies also bind to at least one additional Siglec protein. In some embodiments, anti-CD33 antibodies modulate one or more activities of at least one additional Siglec protein or cells expressing at least one additional Siglec protein.

[0231] CD33 ligand

[0232] The CD33 proteins of the present disclosure can interact with (eg, bind to) one or more CD33 ligands.

[0233] Exemplary CD33 ligands include, but are not limited to, sialic acid, sialic acid-containing glycolipids, sialic acid-containing glycoproteins, α-2,6-linked sialic acid-containing glycolipids, α-2,6-linked sialic acid-containing glycoproteins, α-2,3-linked sialic acid-containing glycolipids, α-2,3-linked sialic acid-containing glycoproteins, α-1-acid glycoprotein (AGP), CD24 protein, gangliosides (e.g., glycolipids containing ceramide linked to sialylated glycans), secreted mucins, CD33 ligands expressed on erythrocytes, CD33 ligands expressed on bacterial cells, CD33 ligands expressed on apoptotic cells, CD33 ligands expressed on tumor cells, CD33 ligands expressed on viruses, CD33 ligands expressed on dendritic cells, CD33 ligands expressed on neural cells, CD33 ligands expressed on glial cells, and CD33 ligands expressed on glial cells. CD33 ligands, CD33 ligands expressed on microglia, CD33 ligands expressed on astrocytes, CD33 ligands on beta-amyloid plaques, CD33 ligands on Tau tangles, CD33 ligands on pathogenic proteins, CD33 ligands on pathogenic peptides, CD33 ligands expressed on macrophages, CD33 ligands expressed on natural killer cells, CD33 ligands expressed on T cells, CD33 ligands expressed on helper T cells, CD33 ligands expressed on cytotoxic T cells, CD33 ligands expressed on B cells, CD33 ligands expressed on tumor-embedded immunosuppressive dendritic cells, CD33 ligands expressed on tumor-embedded immunosuppressive macrophages, CD33 ligands expressed on myeloid-derived suppressor cells, and CD33 ligands expressed on regulatory T cells. In some embodiments, the CD33 ligands of the present disclosure are gangliosides. Gangliosides generally share a common lacto-ceramide core and one or more sialic acid residues.

[0234] Further examples of suitable ganglioside ligands are listed in Table A. In general, gangliosides are molecules composed of glycosphingolipids with one or more sialic acids (eg, n-acetyl-neuraminic acid, NANA) attached to a sugar chain.

[0235] Table A: Structures of exemplary ganglioside CD33 ligands

[0236]

[0237]

[0238] anti-CD33 antibody

[0239] Certain aspects of the present disclosure relate to anti-CD33 antibodies comprising one or more improved and / or enhanced functional characteristics. In some embodiments, the anti-CD33 antibodies of the present disclosure comprise one or more improved and / or enhanced functional characteristics relative to a reference or control antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). In some embodiments, the anti-CD33 antibodies of the present disclosure have an affinity for CD33 (e.g., human CD33) that is greater than the affinity of a reference or control anti-CD33 antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). In some embodiments, the anti-CD33 antibodies of the present disclosure bind to human cells, e.g., human primary dendritic cells, at a half-maximal effective concentration (EC 50 ) is lower than the half-maximal effective concentration of a reference or control antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). In some embodiments, the anti-CD33 antibodies of the present disclosure reduce cellular levels of CD33 (e.g., reduce or decrease cell surface levels) at a half-maximal effective concentration (EC 50 ) is lower than the half-maximal effective concentration of a reference or control antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the sequence of SEQ ID NO: 3 and a light chain variable region comprising the sequence of SEQ ID NO: 4).

[0240] Cellular levels of CD33 may refer to, but are not limited to, cell surface levels of CD33, intracellular levels of CD33, and total levels of CD33. In some embodiments, a reduction in cellular levels of CD33 includes a reduction in cell surface levels of CD33. In some embodiments, an anti-CD33 antibody of the present disclosure that reduces cellular levels of CD33 (e.g., cell surface levels of CD33) has one or more of the following characteristics: (1) inhibiting or reducing one or more CD33 activities; (2) the ability to inhibit or reduce binding of CD33 to one or more of its ligands; (3) the ability to reduce CD33 expression in CD33-expressing cells; (4) the ability to interact with, bind to, or recognize CD33 protein; (5) the ability to specifically interact with or bind to CD33 protein; and (6) the ability to treat, ameliorate, or prevent any aspect of a disease or condition described or contemplated herein.

[0241] The anti-CD33 antibodies of the present disclosure may have nanomolar or even picomolar affinities for the target antigen (e.g., human CD33). In certain embodiments, the dissociation constant (K) of the antibody is D ) is from about 0.001 nM to about 100 nM. In certain embodiments, the K D In certain embodiments, the K of an antibody is about 0.01 nM to about 10 nM. D In some embodiments, the K of the antibody is about 0.23 to about 3.88 nM. D In some embodiments, the antibody has a K of less than or equal to about 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9.5 nM, 9 nM, 8.5 nM, 8 nM, 7.5 nM, 7 nM, 6.5 nM, 6 nM, 5.5 nM, 5 nM, 4.5 nM, 4 nM, 3.5 nM, 3 nM, 2.5 nM, 2 nM, 1.5 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM, .05 nM, .01 nM, or .005 nM. D Less than about 0.40 nM. In some embodiments, the K D Less than about 0.30 nM. In some embodiments, the K D In some embodiments, the KD of the antibody is less than about 0.20 nM. In some embodiments, the KD of the antibody is less than about 0.10 nM. D In some embodiments, the antibody has a K D That is, the antibody has a K of greater than or equal to about 0.001 nM, 0.005 nM, 0.01 nM, 0.05 nM, 0.1 nM, 0.2 nM, 0.3 nM, 0.4 nM, 0.5 nM, 0.6 nM, 0.7 nM, 0.8 nM, 0.9 nM, 1 nM, 1.5 nM, 2 nM, 2.5 nM, 3 nM 3.5 nM, 4 nM, 4.5 nM, 5 nM, 5.5 nM, 6 nM, 6.5 nM, 7 nM, 7.5 nM, 8 nM, 8.5 nM, 9 nM, 9.5 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, or 90 nM. DThe upper limit may be about 100nM, 90nM, 80nM, 70nM, 60nM, 50nM, 40nM, 30nM, 20nM, 10nM, 9.5nM, 9nM, 8.5nM, 8nM, 7.5nM, 7nM, 6.5nM, 6nM, 5.5nM, 5nM, 4.5nM, 4nM, 3.5nM, 3nM, 2.5nM, 2nM, 1.5nM, 1nM, 0.9nM, 0.8nM, 0.7nM, 0. 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM, 0.05 nM, 0.01 nM or 0.005 nM and the lower limit independently selected is about 0.001 nM, 0.005 nM, 0.01 nM, 0.05 nM, 0.1 nM, 0.2 nM, 0.3 nM, 0.4 nM, 0.5 nM, 0.6 nM, 0.7 nM, 0.8 nM, 0.9 nM, 1 nM, 1.5 nM, 2 nM, 2.5 nM, 3 nM In some embodiments, the antibody has an affinity range of 3.5 nM, 4 nM, 4.5 nM, 5 nM, 5.5 nM, 6 nM, 6.5 nM, 7 nM, 7.5 nM, 8 nM, 8.5 nM, 9 nM, 9.5 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, or 90 nM, wherein the lower limit is less than the upper limit. D is any of about 10 nM, about 9 nM, about 8 nM, about 7 nM, about 6 nM, about 5 nM, about 4 nM, about 3 nM, about 2 nM, about 1 nM, about 900 pM, about 800 pM, about 700 pM, about 600 pM, about 500 pM, about 400 pM, about 300 pM, about 200 pM, or about 100 pM. Various methods of measuring antibody affinity are known in the art, including, for example, using surface plasmon resonance or biomembrane interferometry (see, e.g., Example 3 below). In some embodiments, the K of CD33 is determined at a temperature of about 25°C. D In some embodiments, the K of CD33 is determined at a temperature of about 4°C. D In some embodiments, K is determined using a monovalent antibody (e.g., Fab) or a monovalent form of a full-length antibody. D In some embodiments, bivalent antibodies and monomeric recombinant CD33 protein are used to determine K D .

[0242] In some embodiments, the dissociation constant (K) of an anti-CD33 antibody of the present disclosure for CD33 is D) is lower than that of a reference anti-CD33 antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). In some embodiments, the K of an anti-CD33 antibody of the present disclosure for a target (e.g., human CD33) is D Compared to the K of a reference anti-CD33 antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4) for the target D In some embodiments, the K of an anti-CD33 antibody of the present disclosure for a target (e.g., human CD33) is lower than that of an anti-CD33 antibody of the present disclosure. D Compared to the K of a reference anti-CD33 antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4) for the target D In some embodiments, the K of an anti-CD33 antibody of the present disclosure for human CD33 is at least about 1 fold, at least about 1.1 fold, at least about 1.5 fold, at least about 2 fold, at least about 3 fold, at least about 4 fold, at least about 5 fold, at least about 6 fold, at least about 7 fold, at least about 8 fold, at least about 9 fold, at least about 10 fold, at least about 12.5 fold, at least about 15 fold, at least about 17.5 fold, at least about 20 fold, at least about 22.5 fold, at least about 25 fold, at least about 27.5 fold, at least about 30 fold, at least about 50 fold, or at least about 100 fold lower. D The K of the anti-CD33 antibodies of the present disclosure against human CD33 is at least 7 times greater than that of an anti-CD33 antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4. D At least 1.8 times greater than an anti-CD33 antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4. In some embodiments, affinity is measured by surface plasmon resonance. In some embodiments, affinity is measured at a temperature of about 25° C. In some embodiments, affinity is measured at a temperature of about 4° C. In some embodiments, affinity is measured using an experimental method as described in the Examples below.

[0243] The anti-CD33 antibodies of the present disclosure can be administered at a half-maximal effective concentration (EC 50 In certain embodiments, the EC of the antibody is 50 In certain embodiments, the EC of an antibody is from about 0.1 pM to about 500 pM. 50 In certain embodiments, the EC of an antibody is from about 1 pM to about 250 pM. 50 In certain embodiments, the EC of an antibody is about 27 pM to about 40 pM. 50 In some embodiments, the EC of the antibody is about 78 pM to about 40 pM. 50 Less than or equal to about 500 pM, 400 pM, 300 pM, 250 pM, 225 pM, 200 pM, 175 pM, 150 pM, 125 pM, 100 pM, 75 pM, 50 pM, 25 pM, 10 pM, 1 pM, or 0.5 pM. In some embodiments, the EC of the antibody is less than or equal to about 500 pM, 400 pM, 300 pM, 250 pM, 225 pM, 200 pM, 175 pM, 150 pM, 125 pM, 100 pM, 75 pM, 50 pM, 25 pM, 10 pM, 1 pM, or 0.5 pM. 50 Less than about 74.3 pM. In some embodiments, the EC of the antibody 50 greater than or equal to about 0.1 pM, 0.5 pM, 1 pM, 10 pM, 25 pM, 50 pM, 75 pM, 100 pM, 125 pM, 150 pM, 175 pM, 200 pM, 225 pM, 250 pM, 300 pM, or 400 pM. That is, the EC of the antibody 50 The EC of an antibody may be any one of a range having an upper limit of about 500 pM, 400 pM, 300 pM, 250 pM, 225 pM, 200 pM, 175 pM, 150 pM, 125 pM, 100 pM, 75 pM, 50 pM, 25 pM, 10 pM, 1 pM or 0.5 pM and an independently selected lower limit of about 0.1 pM, 0.5 pM, 1 pM, 10 pM, 25 pM, 50 pM, 75 pM, 100 pM, 125 pM, 150 pM, 175 pM, 200 pM, 225 pM, 250 pM, 300 pM or 400 pM, wherein the lower limit is less than the upper limit. In some embodiments, the EC of an antibody may be any one of a range having an upper limit of about 500 pM, 400 pM, 300 pM, 250 pM, 225 pM, 100 pM, 75 pM, 50 pM, 25 pM, 10 pM, 1 pM or 0.5 pM and an independently selected lower limit of about 0.1 pM, 0.5 pM, 1 pM, 10 pM, 25 pM, 50 pM, 75 pM, 100 pM, 125 pM, 150 pM, 175 pM, 200 pM, 225 pM, 250 pM, 300 pM or 400 pM 50is about 1 pM, 2 pM, 3 pM, 4 pM, 5 pM, 6 pM, 7 pM, 8 pM, 9 pM, 10 pM, 15 pM, 20 pM, 25 pM, 30 pM, 35 pM, 40 pM, 45 pM, 50 pM, 55 pM, 60 pM, 65 pM, 70 pM, 75 pM, 80 pM, 85 pM, 90 pM, 95 ... Any of 100 pM, 105 pM, 110 pM, 115 pM, 120 pM, 125 pM, 130 pM, 135 pM, 140 pM, 145 pM, 150 pM, 155 pM, 160 pM, 165 pM, 170 pM, 175 pM, 180 pM, 185 pM, 190 pM, 195 pM or 200 pM. 50 Various methods of determining the value of EC are known in the art, including, for example, by flow cytometry (see, e.g., Example 3 below). 50 In vitro measurements were performed using primary human dendritic cells. 50 In some embodiments, EC 50 In some embodiments, EC 50 The EC is measured in vitro using cultured cells transfected with human CD33. In some embodiments, EC is measured at a temperature of about 4°C. 50 In some embodiments, EC is measured at a temperature of about 25°C. 50 In some embodiments, EC is measured at a temperature of about 35°C. 50 In some embodiments, EC is measured at a temperature of about 37°C. 50 In some embodiments, EC 50 The assay is performed using a monovalent antibody (e.g., Fab) or a monovalent full-length antibody. 50 is determined using an antibody comprising a constant region that exhibits enhanced Fc receptor binding. 50 It is assayed using antibodies containing constant regions that show reduced Fc receptor binding.

[0244] In some embodiments, the anti-CD33 antibodies of the present disclosure have a lower EC than a reference anti-CD33 antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). 50In some embodiments, the anti-CD33 antibodies of the present disclosure reduce the cellular levels of CD33 (e.g., reduce or decrease cell surface levels) and their EC 50 EC of a reference anti-CD33 antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4) 50 In some embodiments, the anti-CD33 antibodies of the present disclosure reduce cellular levels of CD33 (e.g., decrease or reduce cell surface levels) by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99%. 50 EC of a reference anti-CD33 antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4) 50 In some embodiments, the EC of an anti-CD33 antibody of the present disclosure is at least about 1 fold, at least about 1.1 fold, at least about 1.5 fold, at least about 2 fold, at least about 3 fold, at least about 4 fold, at least about 5 fold, at least about 6 fold, at least about 7 fold, at least about 8 fold, at least about 9 fold, at least about 10 fold, at least about 12.5 fold, at least about 15 fold, at least about 17.5 fold, at least about 20 fold, at least about 22.5 fold, at least about 25 fold, at least about 27.5 fold, at least about 30 fold, at least about 50 fold, or at least about 100 fold lower. 50 At least 1.2-fold to 1.6-fold or 1.1-fold to 1.6-fold lower than an anti-CD33 antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4. In some embodiments, ECs are measured in vitro using primary human dendritic cells. 50 In some embodiments, EC 50 In some embodiments, EC 50 In some embodiments, EC 50 ECs are measured in vitro using cultured cells transfected with human CD33. In some embodiments, ECs are measured by flow cytometry. 50In some embodiments, EC is measured at a temperature of about 25°C. 50 In some embodiments, EC is measured at a temperature of about 35°C. 50 In some embodiments, EC is measured at a temperature of about 37°C. 50 In some embodiments, EC 50 is determined using an antibody comprising a constant region that exhibits enhanced Fc receptor binding. 50 EC is measured using an antibody comprising a constant region that exhibits reduced Fc receptor binding. In some embodiments, EC is measured using the assay described in Example 3 below. 50 .

[0245] Any cell-based in vitro assay or suitable in vivo model described herein or known in the art can be used to measure inhibition of the interaction (eg, binding) between CD33 and one or more CD33 ligands. In some embodiments, an anti-CD33 antibody of the present disclosure inhibits the interaction (e.g., binding) between CD33 and one or more CD33 ligands by at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, %, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more.

[0246] In some embodiments, the anti-CD33 antibodies of the present disclosure inhibit cell surface clustering of CD33. In some embodiments, the anti-CD33 antibodies of the present disclosure inhibit one or more activities of the CD33 protein, including, but not limited to, counteracting one or more phosphorylation of Tyr-340 and Tyr-358 by Src family tyrosine kinases (such as LCK and FYN); recruitment and binding of tyrosine-specific protein phosphatases SHP1 and SHP2; recruitment and binding of PLC-γ1, which can serve as a guanine nucleotide exchange factor for Dynamin-1; recruitment and binding of SH2 domain-containing proteins (e.g., Crk1); recruitment and binding of spleen tyrosine kinase Syk; and recruitment of SH3-SH2-SH3 growth factor. recruitment and binding of factor receptor binding protein 2 (Grb2); recruitment and binding of multiple SH2-containing proteins; phosphorylation of Ser-307 and Ser-342 by protein kinase C; modulation of expression of one or more anti-inflammatory cytokines, IL-4, IL-10, IL-13, IL-35, IL-16, TGF-β, IL-1Ra, G-CSF, and soluble receptors for TNF, INF-β1a, INF-β1b, or IL-6 in monocytes, macrophages, T cells, dendritic cells, neutrophils, and / or microglia; reduction of intracellular calcium mobilization; or microglial cells to regulate the expression of one or more proinflammatory cytokines IFN-a4, IFN-b, IL-1β, TNF-α, IL-6, IL-8, CRP, IL-20 family members, LIF, IFN-γ, OSM, CNTF, GM-CSF, IL-11, IL-12, IL-17, IL-18, IL-23, CXCL10, IL-33, CRP, IL-33, MCP-1 and MIP-1-β; regulate one or more selected from C1qa, C1qB, C1qC, C1s, C1R, C4, C2, C3, ITGB2, HMOX1, LAT2, CASP1, CSTA, expression of proteins such as VSIG4, MS4A4A, C3AR1, GPX1, TyroBP, ALOX5AP, ITGAM, SLC7A7, CD4, ITGAX, PYCARD, CD14, CD16, HLA-DR, and CCR2; inhibit extracellular signal-regulated kinase (ERK) phosphorylation; reduce tyrosine phosphorylation on multiple cellular proteins; regulate CC chemokine receptor 7 (CCR7) expression; inhibit chemotaxis of microglia toward cells expressing CCL19 and CCL21; activate phosphoinositide 3-kinase; and reduce cell growth of monocytes, macrophages, T cells, dendritic cells, and / or microglia.Reduce T cell proliferation induced by dendritic cells, bone marrow-derived dendritic cells, monocytes, microglia, M1 microglia, activated M1 microglia, M2 microglia, macrophages, M1 macrophages, activated M1 macrophages, and / or M2 macrophages; inhibit osteoclast production, reduce the rate of osteoclast formation, or both; reduce neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 Microglial cell survival; reduces proliferation of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia; inhibits proliferation of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated the migration of M1 microglia and / or M2 microglia; reduce one or more functions of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia and / or M2 microglia; inhibit neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia and / or M2 microglia Maturation of glial cells, M1 microglia, activated M1 microglia and / or M2 microglia; Increase cell death and apoptosis of monocytes, macrophages, T cells, dendritic cells, neutrophils and / or microglia; Reduce phagocytic activity of monocytes, macrophages, T cells, dendritic cells, neutrophils and / or microglia; Reduce proliferation of monocytes, macrophages, T cells, dendritic cells, neutrophils and / or microglia; Reduce overall function of monocytes, macrophages, T cells, dendritic cells, neutrophils and / or microglia; Phosphorylate ITAM-containing receptors; Phosphorylate signaling molecules that mediate ITAM signaling;Reduce the activation of pattern recognition receptors; reduce the activation of Toll-like receptors; reduce damage-associated activation of cell and protein debris clearance; interaction between CD33 and one or more of its ligands; interaction between CD33 and co-receptors such as CD64; reduce one or more clearances selected from apoptotic neurons clearance, neural tissue debris clearance, dysfunctional synaptic clearance, non-neural tissue debris clearance, bacteria or other foreign matter clearance, pathogenic protein clearance and tumor cell clearance; inhibit one or more apoptotic neurons, neural tissue debris, non-neural tissue debris, bacteria, phagocytosis of other foreign bodies, pathogenic proteins, pathogenic peptides, pathogenic nucleic acids, pathogenic lipids or tumor cells; inhibiting the clearance of pathogenic nucleic acids (such as pathogenic nucleic acids are antisense GGCCCC (G2C4) repeat expansion RNA); activating proteins selected from beta-amyloid protein, beta-amyloid plaques, amyloid precursor protein or fragments thereof, Tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin protein, calcitonin, superoxide dismutase, Ataxin, ataxin 1, ataxin 2, ataxin 3, ataxin 7, ataxin 8, ataxin 10, Lewy bodies, atrial natriuretic peptide, islet amylin, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, beta-2 microglobulin, gelsolin, keratoepithelin, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation product, dipeptide repeat (DPR) peptide, glycine- The invention relates to a novel method for the clearance of pathogenic proteins such as alanine (GA) repeat peptides, glycine-proline (GP) repeat peptides, glycine-arginine (GR) repeat peptides, proline-alanine (PA) repeat peptides, ubiquitin and proline-arginine (PR) repeat peptides; and the inhibition of beneficial immune responses to different types of cancers selected from bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, acute myeloid leukemia, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma and thyroid cancer.Suppressing beneficial immune responses to different types of neurological disorders selected from dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, amyotrophic lateral sclerosis, Huntington's disease, tauopathy, Nasu-Hakola disease, stroke, acute trauma, chronic trauma, essential tremor, Behcet's disease, Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, Shy-Drager syndrome, progressive supranuclear palsy, corticobasal degeneration, acute disseminated encephalomyelitis, granulomatous disorders, sarcoidosis, diseases of aging, epilepsy, spinal cord injury, traumatic brain injury, age-related macular degeneration, glaucoma, retinitis pigmentosa, retinal degeneration and multiple sclerosis; inhibiting beneficial immune responses to different types of inflammatory and infectious conditions selected from lupus, acute and chronic colitis, wound healing, Crohn's disease, inflammatory bowel disease, ulcerative colitis, obesity, malaria, respiratory tract infections, sepsis, eye infections, systemic infections, lupus, arthritis, low bone density, osteoporosis, osteogenesis, osteosclerotic diseases and Paget's disease of bone; binding to CD33 ligand on tumor cells; binding to dendritic cells, The invention relates to a novel method for the treatment of leukemia, melanoma, and / or leukemia-derived dendritic cells, monocytes, microglia, T cells, neutrophils and / or macrophages; inhibits tumor cell killing by one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells or cytotoxic T cells; inhibits the anti-tumor cell proliferation activity of one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells or cytotoxic T cells; inhibits ... the anti-tumor cell metastatic activity of one or more of cells, macrophages, dendritic cells, myeloid-derived dendritic cells, neutrophils, T cells, helper T cells or cytotoxic T cells; promote immunosuppressive dendritic cells, immunosuppressive macrophages, myeloid-derived suppressor cells, tumor-associated macrophages or regulatory T cells; inhibit one or more receptors containing ITAM motifs, such as TREM1, TREM2, FcgR, DAP10 and DAP12; inhibit one or more receptors containing the motif D / Ex0–2YxxL / IX6–8YxxL / I (SEQ ID NO: 104); inhibit signaling through one or more pattern recognition receptors (PRRs), such as receptors that recognize pathogen-associated molecular patterns (PAMPs) and receptors that recognize damage-associated molecular patterns (DAMPs); inhibit the inhibition of signaling through one or more Toll-like receptors; inhibit the JAK-STAT signaling pathway; inhibit nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB); inhibit PLCγ / PKC / calcium mobilization;Inhibit PI3K / Akt, Ras / MAPK signaling; reduce the expression of one or more inflammatory receptors such as CD86 expressed on one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells or cytotoxic T cells; increase the expression of one or more CD33-dependent genes; normalize the expression of disrupted CD33-dependent genes; and reduce the expression of one or more ITAM-dependent genes such as NFAT transcription factors.

[0247] In some embodiments, the anti-CD33 antibodies of the present disclosure exhibit one or more activities of the CD33 protein, including but not limited to: increasing tumor infiltration of CD33; + T cell count; reduce CD14 + Myeloid cells such as tumor-infiltrating CD14 + Myeloid cells and CD14 in the blood + Cellular levels of CD33 in myeloid cells; reduced CD14 + Myeloid cells, tumor-infiltrating CD14 + cells and CD14 in the blood + the number of myeloid cells; reducing the level of PD-L1, PD-L2, B7-H7, B7-H3, CD200R, CD163 and / or CD206 in one or more cells such as myeloid-derived suppressor cells (MDSCs); reducing the tumor growth rate of solid tumors; reducing tumor volume; improving the efficacy of one or more PD-1 inhibitors; improving the efficacy of one or more checkpoint inhibitor therapies and / or immunomodulatory therapies (such as checkpoint inhibitor therapies and / or immunomodulatory therapies targeting one or more of CTL4, adenosine pathway, PD-L1, PD-L2, OX40, TIM3, LAG3 or any combination thereof); improving the efficacy of one or more chemotherapeutic agents, optionally wherein the one or more chemotherapeutic agents are gemcitabine, capecitabine, anthracyclines, doxorubicin, Epirubicin Taxanes, paclitaxel Docetaxel 5-fluorouracil (5-FU), cyclophosphamide Carboplatin Oxaliplatin Folic acid, temozolomide and any combination thereof; increasing the proliferation of T cells in the presence of myeloid-derived suppressor cells (MDSCs); inhibiting the differentiation, survival and / or one or more functions of myeloid-derived suppressor cells (MDSCs); and when conjugated to chemical or radioactive toxins, killing immunosuppressive non-tumorigenic myeloid cells and / or non-tumorigenic CD14-expressing cells that express CD33 in solid tumors and associated blood vessels.

[0248] In some embodiments, the anti-CD33 antibodies inhibit the interaction (e.g., binding) between a CD33 protein of the present disclosure and one or more CD33 ligands, including but not limited to CD33 ligands expressed on erythrocytes, CD33 ligands expressed on bacterial cells, CD33 ligands expressed on apoptotic cells, CD33 ligands expressed on tumor cells, CD33 ligands expressed on viruses, CD33 ligands expressed on dendritic cells, CD33 ligands expressed on neural cells, CD33 ligands expressed on glial cells, CD33 ligands expressed on microglial cells, CD33 ligands expressed on astrocytes, CD33 ligands on beta-amyloid plaques, CD33 ligands on Tau tangles, CD33 ligands on pathogenic proteins, CD33 ligands on pathogenic peptides, CD33 ligands expressed on macrophages, natural killer (NK) cells, CD33 ligand expressed on cells, CD33 ligand expressed on T cells, CD33 ligand expressed on helper T cells, CD33 ligand expressed on cytotoxic T cells, CD33 ligand expressed on B cells, CD33 ligand expressed on tumor-embedded immunosuppressive dendritic cells, CD33 ligand expressed on tumor-embedded immunosuppressive macrophages, CD33 ligand expressed on myeloid-derived suppressor cells, and CD33 ligand expressed on regulatory T cells. Expressed CD33 ligand, secretory mucin, sialic acid, sialic acid-containing glycolipids, sialic acid-containing glycoproteins, α-2,6-linked sialic acid-containing glycolipids, α-2,6-linked sialic acid-containing glycoproteins, α-2,3-linked sialic acid-containing glycolipids, α-2,3-linked sialic acid-containing glycoproteins, α-2,3-linked sialic acid-containing glycoproteins, α-1-acid glycoprotein (AGP), CD24 protein, and gangliosides.

[0249] In some embodiments, the anti-CD33 antibodies of the present disclosure bind to the CD33 proteins of the present disclosure expressed on the cell surface, and the naked antibodies inhibit the interaction (e.g., binding) between the CD33 proteins and one or more CD33 ligands. In some embodiments, the anti-CD33 antibodies of the present disclosure that bind to the CD33 proteins of the present disclosure inhibit the interaction (e.g., binding) between the CD33 proteins and one or more CD33 ligands by reducing the effective level of CD33 on the cell surface or within the cell that is available for interaction with these proteins. In some embodiments, the anti-CD33 antibodies of the present disclosure that bind to the CD33 proteins of the present disclosure inhibit the interaction (e.g., binding) between the CD33 proteins and one or more CD33 ligands by inducing degradation of CD33.

[0250] As used herein, the level of CD33 can refer to the expression level of a gene encoding CD33; the expression level of one or more transcripts encoding CD33; the expression level of CD33 protein; and / or the amount of CD33 protein present in a cell and / or on the cell surface. Any method known in the art for measuring gene expression, transcription, translation, and / or protein abundance or localization levels can be used to determine the level of CD33.

[0251] In addition, the anti-CD33 antibodies of the present disclosure can be used to prevent, reduce the risk of, or treat dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, amyotrophic lateral sclerosis, Huntington's disease, tauopathy, Nasu-Hakola disease, stroke, acute trauma, chronic trauma, lupus, acute and chronic colitis, rheumatoid arthritis, wound healing, Crohn's disease, inflammatory bowel disease, ulcerative colitis, obesity, malaria, essential tremor, central nervous system lupus, Behçet's disease, Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, Shy-Drager syndrome, progressive supranuclear palsy, corticobasal degeneration, acute disseminated encephalomyelitis, granulomatous disorders, sarcoidosis, diseases of aging, epilepsy, spinal cord injury, traumatic brain injury, age-related macular degeneration, glaucoma, retinitis pigmentosa, retinal degeneration Sex, respiratory infections, sepsis, eye infections, systemic infections, lupus, arthritis, multiple sclerosis, low bone density, osteoporosis, osteogenesis, osteosclerotic diseases, Paget's disease of bone, cancer, including bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), multiple myeloma, polycythemia vera, essential thrombocythemia, primary or idiopathic myelofibrosis, primary or idiopathic myelosclerosis, myeloid-derived tumors, tumors expressing CD33, thyroid cancer, infections, CNS herpes, parasitic infections, trypanosome infections, Cruz infections, Pseudomonas aeruginosa (Pseudomonas aeruginosa) aeruginosa infection, Leishmania donovani infection, Group B Streptococcus infection, Campylobacter jejuni infection, Neisseria meningitidis infection, HIV type 1 and / or Haemophilus influenza. In some embodiments, the anti-CD33 antibodies of the present disclosure can be used to induce or promote the survival, maturation, functionality, migration or proliferation of one or more immune cells in an individual in need thereof; or to reduce the activity, functionality or survival of regulatory T cells, tumor-embedded immunosuppressive dendritic cells, tumor-embedded immunosuppressive macrophages, myeloid-derived suppressor cells, tumor-associated macrophages, acute myeloid leukemia (AML) cells, chronic lymphocytic leukemia (CLL) cells and / or chronic myeloid leukemia (CML) cells in an individual in need thereof. In some embodiments, the anti-CD33 antibodies of the present disclosure are monoclonal antibodies.

[0252] In some embodiments, the isolated anti-CD33 antibodies of the present disclosure reduce the cellular level of CD33 (e.g., cell surface level, intracellular level, and / or total level). In some embodiments, the isolated anti-CD33 antibodies of the present disclosure induce downregulation of CD33. In some embodiments, the isolated anti-CD33 antibodies of the present disclosure induce cleavage of CD33. In some embodiments, the isolated anti-CD33 antibodies of the present disclosure induce internalization of CD33. In some embodiments, the isolated anti-CD33 antibodies of the present disclosure induce shedding of CD33. In some embodiments, the isolated anti-CD33 antibodies of the present disclosure induce degradation of CD33. In some embodiments, the isolated anti-CD33 antibodies of the present disclosure induce desensitization of CD33. In some embodiments, the isolated anti-CD33 antibodies of the present disclosure act as ligand mimics to transiently activate CD33. In some embodiments, the isolated anti-CD33 antibodies of the present invention act as ligand mimics and transiently activate CD33 before inducing a decrease in the cellular level of CD33 and / or inhibiting the interaction (e.g., binding) between CD33 and one or more CD33 ligands. In some embodiments, the isolated anti-CD33 antibodies of the present invention act as ligand mimics and transiently activate CD33 before inducing CD33 degradation. In some embodiments, the isolated anti-CD33 antibodies of the present invention act as ligand mimics and transiently activate CD33 before inducing CD33 cleavage. In some embodiments, the isolated anti-CD33 antibodies of the present invention act as ligand mimics and transiently activate CD33 before inducing CD33 internalization. In some embodiments, the isolated anti-CD33 antibodies of the present invention act as ligand mimics and transiently activate CD33 before inducing CD33 shedding. In some embodiments, the isolated anti-CD33 antibodies of the present invention act as ligand mimics and transiently activate CD33 before inducing CD33 expression downregulation. In some embodiments, the isolated anti-CD33 antibodies of the present disclosure act as ligand mimics and transiently activate CD33 before inducing CD33 desensitization.

[0253] In some embodiments, the isolated anti-CD33 antibodies of the present disclosure are human antibodies, humanized antibodies, bispecific antibodies, monoclonal antibodies, multivalent antibodies, or chimeric antibodies. Exemplary descriptions of such antibodies can be found throughout this disclosure.

[0254] In some embodiments, the anti-CD33 antibodies of the present disclosure bind to human CD33 or a homolog thereof, including but not limited to mammalian CD33 proteins. In some embodiments, the anti-CD33 antibodies of the present disclosure bind specifically to human CD33. In some embodiments, the anti-CD33 antibodies of the present disclosure bind to human CD33 and do not cross-react with CD33 orthologs or homologs from other species. In some embodiments, the anti-CD33 antibodies of the present disclosure bind to human CD33 but do not bind to cynomolgus monkey CD33. In some embodiments, the anti-CD33 antibodies of the present disclosure bind to both human CD33 and cynomolgus monkey CD33.

[0255] In some embodiments, the anti-CD33 antibodies of the present disclosure bind to the CD33 proteins of the present disclosure expressed on the cell surface and, upon binding to the surface-expressed CD33 proteins, modulate (e.g., induce or inhibit) one or more CD33 activities of the present disclosure. In some embodiments, the anti-CD33 antibodies of the present disclosure are inert antibodies.

[0256] Anti-CD33 antibody binding region

[0257] In some embodiments, the anti-CD33 antibodies of the present disclosure may bind to a conformational epitope. In some embodiments, the anti-CD33 antibodies of the present disclosure may bind to a discontinuous CD33 epitope. In some embodiments, the discontinuous CD33 epitope comprises two or more peptides, three or more peptides, four or more peptides, five or more peptides, six or more peptides, seven or more peptides, eight or more peptides, nine or more peptides, or ten or more peptides. In some embodiments, the anti-CD33 antibodies of the present disclosure may bind to a CD33 epitope comprising one or more peptides. As disclosed herein, a CD33 epitope can comprise one or more peptides comprising 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, or 20 or more amino acid residues of the amino acid sequence of SEQ ID NO: 1, or 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, or 20 or more amino acid residues of a mammalian CD33 protein corresponding to the amino acid sequence of SEQ ID NO: 1.

[0258] In some embodiments, the anti-CD33 antibodies of the present disclosure bind to an epitope of human CD33 that is identical to or overlaps with an epitope of CD33 bound by an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4. In some embodiments, the anti-CD33 antibodies of the present disclosure bind to an epitope of CD33 that is substantially identical to an epitope bound by an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4.

[0259] In some embodiments, the anti-CD33 antibodies of the present disclosure competitively inhibit the binding of an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4. In some embodiments, the anti-CD33 antibodies of the present disclosure compete for binding to CD33 (e.g., human CD33) with an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4.

[0260] In some embodiments, the anti-CD33 antibodies of the present disclosure competitively inhibit the binding of at least one antibody selected from any of the antibodies listed in Table 7, Table 8, Table 9, Table 10, Table 11, and Table 12. In some embodiments, the anti-CD33 antibodies of the present disclosure competitively inhibit the binding of at least one antibody selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof. In some embodiments, when the anti-CD33 antibodies of the present disclosure are selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, when binding of one or more of 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof, to CD33 is reduced by an amount ranging from about 50% to about 100% compared to binding to CD33 in the absence of the anti-CD33 antibody,The anti-CD33 antibody is selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7 34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof, competes for binding to CD33. In some embodiments, when the anti-CD33 antibodies of the present disclosure are selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6 C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C when binding of one or more of the anti-CD33 antibodies selected from the group consisting of 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof, to CD33 is reduced by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100%, compared to binding to CD33 in the absence of the anti-CD33 antibody,The anti-CD33 antibody is selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7 34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof, competes for binding to CD33. In some embodiments, the compound selected from the group consisting of 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H3 0, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof, wherein the anti-CD33 antibodies of the present disclosure have 100% reduced binding to CD33.The anti-CD33 antibody substantially completely blocks the activity of 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28 , 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 and 6C7H54, and any combination thereof, binds to CD33. In some embodiments, the anti-CD33 antibody and a monoclonal antibody selected from the group consisting of 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H 28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof, are present in an amount,The amounts correspond to a ratio of 10:1, a ratio of 9:1, a ratio of 8:1, a ratio of 7:1, a ratio of 6:1, a ratio of 5:1, a ratio of 4:1, a ratio of 3:1, a ratio of 2:1, a ratio of 1:1, a ratio of 0.75:1, a ratio of 0.5:1, a ratio of 0.25:1, a ratio of 0.1:1, a ratio of 0.075:1, a ratio of 0.050:1, a ratio of 0.025:1, a ratio of 0.01:1, a ratio of 0.0075:1, a ratio of 0.0050:1, a ratio of 0.0025:1, a ratio of 0.001:1, a ratio of 0.00075:1, a ratio of 0.0005 0:1 ratio, 0.00025:1 ratio, 0.0001: ratio, 1:10 ratio, 1:9 ratio, 1:8 ratio, 1:7 ratio, 1:6 ratio, 1:5 ratio, 1:4 ratio, 1:3 ratio, 1:2 ratio, 1:0.75 ratio, 1:0.5 ratio, 1:0.25 ratio, 1:0.1 ratio, 1:0.075 ratio, 1:0.050 ratio, 1:0.025 ratio, 1:0.01 ratio, 1:0.0075 ratio, 1:0.0050 ratio, 1:0.0025 ratio, 1:0.001 ratio , 1:0.00075, 1:0.00050, 1:0.00025 or 1:0.0001 of an anti-CD33 antibody and 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25 In some embodiments, one or more antibodies selected from the group consisting of C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof.The anti-CD33 antibody is selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30 , 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof, are present in an amount that is about 1.5-fold to 100-fold, or greater than 100-fold excess compared to the amount of one or more antibodies selected from the group consisting of: 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, In some embodiments, the anti-CD33 antibody is used in combination with an antibody selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 7. 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26 , 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6 C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C 7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 and 6C7 The amount of one or more antibodies of H54 and any combination thereof is present in an excess of about 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 35-fold, 40-fold, 45-fold, 50-fold, 55-fold, 60-fold, 65-fold, 70-fold, 75-fold, 80-fold, 85-fold, 90-fold, 95-fold, or 100-fold.

[0261] In some embodiments, the anti-CD33 antibodies of the present disclosure bind to an epitope of human CD33 that is identical to or overlaps with an epitope of CD33 bound by at least one antibody selected from any of the antibodies listed in Table 7, Table 8, Table 9, Table 10, Table 11, and Table 12. In some embodiments, the anti-CD33 antibodies of the present disclosure bind to an epitope of human CD33 that is bound to at least one of 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54 antibodies bind to the same or overlapping epitopes of CD33.

[0262] In some embodiments, the anti-CD33 antibodies of the present disclosure bind to substantially the same CD33 epitope bound by at least one antibody selected from any of the antibodies listed in Table 7, Table 8, Table 9, Table 10, Table 11, and Table 12. In some embodiments, the anti-CD33 antibodies of the present disclosure bind to at least one of the antibodies selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27 , 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54 antibodies bind to substantially the same CD33 epitope. Detailed exemplary methods for mapping epitopes bound by antibodies are provided in "Epitope Mapping Protocols" in Morris (1996) Methods in Molecular Biology (Humana Press, Totowa, NJ), Vol. 66.

[0263] In some embodiments, the anti-CD33 antibodies of the present disclosure compete for binding to CD33 (e.g., human CD33) with one or more antibodies selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 4. 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 and 6C7H54, and any combination thereof.

[0264] Any suitable competition assay or CD33 binding assay known in the art, such as BIAcore analysis, ELISA assay, or flow cytometry, can be used to determine whether an anti-CD33 antibody competes for binding to CD33 with one or more antibodies selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof. In an exemplary competition assay, immobilized CD33 or cells expressing CD33 on their cell surfaces are incubated in a solution containing a first labeled antibody (e.g., human or non-human primate) that binds to CD33 and a second unlabeled antibody that is being tested for its ability to compete with the first antibody for binding to CD33. The second antibody may be present in the hybridoma supernatant. As a control, immobilized CD33 or cells expressing CD33 are incubated in a solution containing the first labeled antibody but not the second unlabeled antibody. Following incubation under conditions permissive for binding of the first antibody to CD33, excess unbound antibody is removed, and the amount of label associated with the immobilized CD33 or CD33-expressing cells is measured. If the amount of label associated with the immobilized CD33 or CD33-expressing cells is significantly reduced in the test sample relative to the control sample, this indicates that the second antibody is competing with the first antibody for binding to CD33. See, Harlow and Lane (1988) Antibodies: A Laboratory Manual Chapter 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).

[0265] Anti-CD33 antibody light chain and heavy chain variable regions

[0266] In some embodiments, the anti-CD33 antibodies of the present disclosure comprise a heavy chain variable region comprising one or more (e.g., one or more, two or more, or all three) HVRs selected from HVR-H1, HVR-H2, and HVR-H3 (as shown in Table 7). In some embodiments, the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3 (as shown in Table 7). In some embodiments, the anti-CD33 antibodies of the present disclosure comprise a light chain variable region comprising one or more (e.g., one or more, two or more, or all three) HVRs selected from HVR-L1, HVR-L2, and HVR-L3 (as shown in Table 8). In some embodiments, the heavy chain variable region comprises HVR-L1, HVR-L2, and HVR-L3 (as shown in Table 8).

[0267] In some embodiments, an anti-CD33 antibody of the present disclosure comprises (a) a light chain variable region comprising at least one, two, or three HVRs selected from HVR-L1, HVR-L2, and HVR-L3 of any one of the antibodies selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, 6C7H54, and any combination thereof;and / or (b) a heavy chain variable region comprising at least one, two or three HVRs selected from HVR-H1, HVR-H2 and HVR-H3 of any antibody selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, 6C7H54, and any combination thereof. In some embodiments, the anti-CD33 antibodies of the present disclosure comprise at least one, two, three, four, five, or six HVRs selected from the following HVRs: (i) HVR-L1 comprising an HVR selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, amino acid sequences of the antibodies comprising: 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54;(ii) HVR-L2 comprises an HVR-L3 selected from the group consisting of 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, amino acid sequences of the antibodies 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54; (iii) HVR-L3 comprises an HVR selected from the group consisting of 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27 , 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54;(iv) HVR-H1 comprises an HVR-H2 selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27 , 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54 (v) HVR-H2 comprises a member selected from the group consisting of 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, amino acid sequences of the antibodies 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54;and (vi) HVR-H3 comprising a member selected from the group consisting of 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27 , 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54. In some embodiments, HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3 comprise EU or Kabat CDRs, Chothia CDRs, or Contact CDRs from The CDR sequence of the antibody is selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof. ;

[0268] In some embodiments, an anti-CD33 antibody of the present disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain comprises one or more of: (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (b) HVR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 52-55; and (c) HVR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 58-62; and / or wherein the heavy chain variable domain comprises one or more of: (a) HVR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 8-30; (b) HVR-H2 comprising an amino acid sequence of SEQ ID NO: 33; and (c) HVR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38-40.

[0269] In some embodiments, the anti-CD33 antibodies of the present disclosure comprise a heavy chain variable domain and a light chain variable domain, wherein (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 8, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 38, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 52, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (b) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 8, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (c) HVR-H1 comprises the amino acid sequence of SEQ ID NO: (d) HVR-H1 comprises the amino acid sequence of SEQ ID NO:9, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:54, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (e) HVR-H1 comprises the amino acid sequence of SEQ ID NO:9, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58. NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:55, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58;(f) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 10, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (g) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 11, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (h) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 12, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (i) HVR-H1 comprises the amino acid sequence of SEQ ID NO:13, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (j) HVR-H1 comprises the amino acid sequence of SEQ ID NO:14, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: (k) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 15, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58;(l) HVR-H1 comprises the amino acid sequence of SEQ ID NO:16, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (m) HVR-H1 comprises the amino acid sequence of SEQ ID NO:17, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (n) HVR-H1 comprises the amino acid sequence of SEQ ID NO:18, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (o) HVR-H1 comprises the amino acid sequence of SEQ ID NO:19, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (p) HVR-H1 comprises the amino acid sequence of SEQ ID NO:20, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: (q) HVR-H1 comprises the amino acid sequence of SEQ ID NO:21, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58;(r) HVR-H1 comprises the amino acid sequence of SEQ ID NO:22, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (s) HVR-H1 comprises the amino acid sequence of SEQ ID NO:23, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (t) HVR-H1 comprises the amino acid sequence of SEQ ID NO:24, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (u) HVR-H1 comprises the amino acid sequence of SEQ ID NO:25, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (v) HVR-H1 comprises the amino acid sequence of SEQ ID NO:26, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: (w) HVR-H1 comprises the amino acid sequence of SEQ ID NO:27, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58;(x) HVR-H1 comprises the amino acid sequence of SEQ ID NO:28, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; (y) HVR-H1 comprises the amino acid sequence of SEQ ID NO:29, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:59; (z) HVR-H1 comprises the amino acid sequence of SEQ ID NO:29, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:60; (aa) HVR-H1 comprises the amino acid sequence of SEQ ID NO:29, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:61; (bb) HVR-H1 comprises the amino acid sequence of SEQ ID NO:29, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: (cc) HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:40, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:59;(dd) HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:40, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:60; (ee) HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:40, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:61; (ff) HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: NO:40, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:62; (gg) HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:60; (hh) HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: (ii) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 23, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 60;(jj) HVR-H1 comprises the amino acid sequence of SEQ ID NO:23, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:62; (kk) HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:59; (ll) HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:61; (mm) HVR-H1 comprises the amino acid sequence of SEQ ID NO:28, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:59; and (nn) HVR-H1 comprises the amino acid sequence of SEQ ID NO:28, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: The amino acid sequence of ID NO:61.

[0270] In some embodiments, the anti-CD33 antibodies of the present disclosure comprise an antibody selected from the group consisting of 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54 any one of the light chain variable regions; and / or selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H 28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54.In some embodiments, an anti-CD33 antibody of the present disclosure comprises a light chain variable region of any one of the antibodies listed in Table 11 or selected from the group consisting of: 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38 , 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H 53 and 6C7H54, and / or the heavy chain variable region of any one of the antibodies listed in Table 12 or selected from the group consisting of: 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H 25. 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C 7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 and 6C7H54.

[0271] In some embodiments, the anti-CD33 antibodies of the present disclosure comprise a light chain variable region comprising an amino acid sequence selected from any one of SEQ ID NOs: 94-103; and / or a heavy chain variable domain comprising an amino acid sequence selected from any one of SEQ ID NOs: 65-93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 94; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 94; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 66. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 95; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 95; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 67. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 95; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 66. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 96; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 96; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 67. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 68. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 98; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 69. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 69. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 94; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 99; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 69. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 70.In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 71. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 72. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 73. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 77. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 78. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 79. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 80. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 81. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 82. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 83. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 84. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 85.In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 86. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 87. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 97; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 88. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 89. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 89. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 89. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 89. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 90. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 90. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 90. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 90. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 91. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 91. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 91.In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 91. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 83. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 83. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 83. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 83.

[0272] In some embodiments, an anti-CD33 antibody is provided, wherein the antibody comprises a V as in any of the embodiments provided above. H and V in any of the embodiments provided above LIn some embodiments, provided herein are anti-CD33 antibodies, wherein the antibody comprises V as in any of the embodiments provided above. H and V in any of the embodiments provided above L In one embodiment, the anti-CD33 antibody of the present disclosure comprises a V sequence selected from the group consisting of SEQ ID NOs: 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, and 93. H Sequence; and V selected from SEQ ID NO: 94, 95, 96, 97, 98, 99, 100, 101, 102 and 103 L In some embodiments, the anti-CD33 antibody comprises an antibody selected from the group consisting of 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7 V of antibodies H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 and 6C7H54 H Sequence and V L sequence

[0273] In some embodiments, provided herein are anti-CD33 antibodies, wherein the antibody comprises a V as in any of the embodiments provided above. H and V in any of the embodiments provided above L In some embodiments, the anti-CD33 antibodies of the present disclosure comprise a V sequence selected from SEQ ID NOs: 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, and 93. HSequence; and V selected from SEQ ID NO: 94, 95, 96, 97, 98, 99, 100, 101, 102 and 103 L In some embodiments, the anti-CD33 antibody comprises an antibody selected from the group consisting of 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7 V of antibodies H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53 and 6C7H54 H Sequence and V L sequence

[0274] In another aspect, the anti-CD33 antibodies of the present disclosure comprise a heavy chain variable domain (V H ) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO:65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92 or 93. In certain embodiments, a V sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence of SEQ ID NO: 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93. HThe sequence comprises substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-CD33 antibody comprising the sequence retains the ability to bind to CD33. In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93. In certain embodiments, a total of 1 to 5 amino acid substitutions, insertions, and / or deletions are present in SEQ ID NO: 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-CD33 antibody comprises the V sequences of SEQ ID NO: 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93. H Sequence, including post-translational modifications of the sequence. In a specific embodiment, the V H Comprising one, two or three HVRs selected from the following: (a) HVR-H1 comprising the amino acid sequence of HVR-H1 shown in Table 7; (b) HVR-H2 comprising the amino acid sequence of HVR-H1 shown in Table 7; (c) HVR-H3 comprising the amino acid sequence of HVR-H3 shown in Table 7.

[0275] In another aspect, the anti-CD33 antibodies of the present disclosure comprise a light chain variable domain (V L ), which has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 94, 95, 96, 97, 98, 99, 100, 101, 102 or 103. In certain embodiments, V has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO: 94, 95, 96, 97, 98, 99, 100, 101, 102 or 103. LThe sequence comprises substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but anti-CD33 antibodies comprising the sequence retain the ability to bind to CD33. In some embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 94, 95, 96, 97, 98, 99, 100, 101, 102, or 103. In certain embodiments, a total of 1 to 5 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 94, 95, 96, 97, 98, 99, 100, 101, 102, or 103.

[0276] In certain embodiments, the substitutions, insertions, or deletions occur in regions outside of the HVRs (i.e., in the FRs). Optionally, the anti-CD33 antibody comprises the V sequences of SEQ ID NOs: 94, 95, 96, 97, 98, 99, 100, 101, 102, or 103. L Sequence, including post-translational modifications of the sequence. In a specific embodiment, V L Comprising one, two or three HVRs selected from the following: (a) HVR-L1 comprising the amino acid sequence of HVR-L1 shown in Table 8; (b) HVR-L2 comprising the amino acid sequence of HVR-L2 shown in Table 8; and (c) HVR-L3 comprising the amino acid sequence of HVR-L3 shown in Table 8.

[0277] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 8; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 38; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H1. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H2. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H3. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H4. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H5. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H6. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H7.

[0278] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 8; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H8.

[0279] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 9; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 54; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H9.

[0280] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 9; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H10.

[0281] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 9; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 55; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H11.

[0282] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 10; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H12.

[0283] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 11; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H13.

[0284] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H14.

[0285] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H15.

[0286] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 14; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H16.

[0287] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 15; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H17.

[0288] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 16; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H18.

[0289] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H19.

[0290] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 18; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H20.

[0291] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 19; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H21.

[0292] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H22.

[0293] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 21; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H23.

[0294] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 22; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H24.

[0295] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H25.

[0296] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 24; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H26.

[0297] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 25; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H27.

[0298] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 26; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H28.

[0299] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 27; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H29.

[0300] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 28; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H30.

[0301] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H31. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H39. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H49.

[0302] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H32. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H40. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H43.

[0303] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H33. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H41. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H50.

[0304] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 62. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H34. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H42. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H44.

[0305] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 40; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H35.

[0306] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 40; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H36.

[0307] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 40; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H37.

[0308] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 40; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 62. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H38.

[0309] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H45.

[0310] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 62. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H46.

[0311] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H47.

[0312] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 62. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H48.

[0313] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H51.

[0314] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H52.

[0315] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H53.

[0316] In some embodiments, provided herein are anti-CD33 antibodies comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-CD33 antibody is the anti-CD33 monoclonal antibody 6C7H54.

[0317] Anti-CD33 antibodies are provided herein. The provided antibodies can be used, for example, for the diagnosis or treatment of CD33-mediated and / or CD33-associated diseases, disorders, or conditions.

[0318] In some embodiments, the anti-CD33 antibody according to any of the above embodiments is a monoclonal antibody, including a humanized antibody and / or a human antibody. In some embodiments, the anti-CD33 antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')2 fragment. In some embodiments, the anti-CD33 antibody is a substantially full-length antibody, e.g., an IgG1 antibody, an IgG2a antibody, or other antibody classes or isotypes as defined herein.

[0319] In some embodiments, the anti-CD33 antibody according to any of the above embodiments may comprise any of the features, alone or in combination, as described below:

[0320] Anti-CD33 antibody binding affinity

[0321] In some embodiments of any of the antibodies provided herein, the antibody has a % saturation of <1 μM, <100 nM, <10 nM, <1 nM, <0.1 nM, <0.01 nM, or <0.001 nM (e.g., 10 -8 M or smaller, for example, 10 -8 M to 10 -13 M, for example, 10 - 9 M to 10 -13 The dissociation constant (Kd) of the antibody is determined by any analytical technique, including any biochemical or biophysical technique, such as ELISA, surface plasmon resonance (SPR), biomembrane interferometry (see, e.g., ForteBio's Octet system), isothermal titration calorimetry (ITC), differential scanning calorimetry (DSC), circular dichroism (CD), stopped-flow analysis, and colorimetric or fluorescent protein melting analysis. In one embodiment, Kd is measured by radiolabeled antigen binding assay (RIA). In some embodiments, RIA is performed using a Fab form of the antibody of interest and its antigen, e.g., as described in Chen et al. J. Mol. Biol. 293:865-881 (1999). In some embodiments, Kd is measured using a BIACORE surface plasmon resonance assay, e.g., an assay using a BIACORE-2000 or BIACORE-3000 (BIAcore, Inc., Piscataway, NJ) at 25°C with about 10 response units (RU) of immobilized antigen CM5 chips. In some embodiments, Kd is determined using a monovalent antibody (e.g., Fab) or a full-length antibody. D In some embodiments, K is determined using a monovalent form of the full-length antibody. D .

[0322] Antibody fragments

[0323] In some embodiments of any of the antibodies provided herein, the antibody is an antibody fragment. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv and scFv fragments, as well as other fragments described below. For a review of certain antibody fragments, see Hudson et al. Nat. Med. 9:129-134 (2003). For a review of scFv fragments, see, for example, WO 93 / 16185; and U.S. Patents Nos. 5,571,894 and 5,587,458. For a discussion of Fab and F(ab')2 fragments comprising salvage receptor binding epitope residues and having extended in vivo half-lives, see U.S. Patent No. 5,869,046.

[0324] Diabodies are antibody fragments with two antigen-binding sites that can be bivalent or bispecific. See, e.g., EP404097; WO 1993 / 01161; Hudson et al. Nat. Med. 9:129-134 (2003). Triabodies and tetrabodies are also described in Hudson et al. Nat. Med. 9:129-134 (2003). Single-domain antibodies are antibody fragments that contain all or part of the heavy chain variable domain or all or part of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (see, e.g., U.S. Patent No. 6,248,516).

[0325] Antibody fragments can be prepared by a variety of techniques including, but not limited to, proteolytic digestion of intact antibodies and production by recombinant host cells (eg, E. coli or phage), as described herein.

[0326] Chimeric and humanized antibodies

[0327] In some embodiments of any of the antibodies provided herein, the antibody is a chimeric antibody. For example, certain chimeric antibodies are described in U.S. Patent No. 4,816,567. In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate such as a monkey) and a human constant region. In another example, a chimeric antibody is a "class-switched" antibody, wherein the class or subclass has been changed from the class or subclass of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.

[0328] In some embodiments of any of the antibodies provided herein, the antibody is a humanized antibody. Typically, non-human antibodies are humanized to reduce immunogenicity to people while maintaining the specificity and affinity of the parent non-human antibody. In certain embodiments, humanized antibodies are substantially non-immunogenic in people. In certain embodiments, the affinity of the humanized antibody to the target is substantially the same as that of an antibody from another species from which the humanized antibody is derived. See, e.g., U.S. Patents 5,530,101, 5,693,761, 5,693,762, and 5,585,089. In certain embodiments, amino acids of antibody variable domains that can be modified without reducing the natural affinity of the antigen-binding domains while reducing their immunogenicity are identified. See, e.g., U.S. Patents 5,766,886 and 5,869,619. Typically, a humanized antibody comprises one or more variable domains wherein HVR (or portions thereof) are derived from non-human antibodies, and FR (or portions thereof) are derived from human antibody sequences. Humanized antibodies optionally also will comprise at least a portion of a human constant region. In some embodiments, some FR residues in the humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.

[0329] Humanized antibodies and methods of making them are reviewed in, for example, Almagro et al. Front. Biosci. 13: 161 9-1633 (2008) and further described in, for example, U.S. Patent Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409. Human framework regions that can be used for humanization include, but are not limited to, framework regions selected using the "best fit" method (see, for example, Sims et al. J. Immunol. 151: 2296 (1993)); framework regions derived from the consensus sequence of human antibodies having a particular subgroup of light or heavy chain variable regions (see, for example, Carter et al. Proc. Natl. Acad. Sci. USA 89:4285 (1992); and Presta et al., J. Immunol. 151:2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson Front. Biosci. 13:1619-1633 (2008)); and framework regions derived from screening FR libraries (see, e.g., Baca et al., J. Biol. Chem. 272:10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271:22611-22618 (1996)).

[0330] Human antibodies

[0331] In some embodiments of any of the antibodies provided herein, the antibody is a human antibody. Human antibodies can be produced using various techniques known in the art. Human antibodies are generally described in van Dijk et al. Curr. Opin. Pharmacol. 5: 368-74 (2001) and Lonberg Curr. Opin. Immunol. 20: 450-459 (2008).

[0332] Human antibodies can be prepared by administering immunogens to transgenic animals, which have been modified to produce complete human antibodies or complete antibodies with human variable regions in response to antigenic attack. Large fragments of the human Ig locus can be used to engineer mouse strains that produce defective mouse antibodies, and it is expected that these mice will produce human antibodies in the absence of mouse antibodies. Large human Ig fragments can maintain large variable gene diversity and the appropriate regulation of antibody production and expression. By utilizing antibody diversification and selection and the mouse mechanism lacking immune tolerance to human proteins, the human antibody library replicated in these mouse strains can produce high-affinity fully human antibodies for any target antigen (including human antigens). Using hybridoma technology, antigen-specific human MAbs with desired specificity can be produced and selected. Certain exemplary methods are described in U.S. Patent No. 5,545,807, EP546,073 and EP 546,073. Also see, for example, description of XENOMOUSE TM US Patent Nos. 6,075,181 and 6,150,584 describe the technology; US Patent No. 5,770,429 describes KM US Patent No. 7,041,870 and description of the technology The human variable regions of intact antibodies produced by such animals can be further modified, for example, by combining with different human constant regions.

[0333] Human antibodies can also be prepared by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, for example, Kozbor J. Immunol. 133: 3001 (1984) and Boerner et al. J. Immunol. 147: 86 (1991)). Human antibodies produced by human B cell hybridoma technology are also described in Li et al. Proc. Natl. Acad. Sci. USA, 103: 3557-3562 (2006). Other methods include, for example, those described in U.S. Patent No. 7,189,826 (describing the production of monoclonal human IgM antibodies from hybridoma cell lines). Also described in Vollmers et al. Histology and Histopathology 20 (3): 927-937 (2005) and Vollmers et al. Methods and Findings in Experimental and Clinical Pharmacology 27 (3): 185-91 (2005) are human hybridoma technology (Trioma technology). Human antibodies can also be produced by isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences can then be combined with desired human constant domains. The technology for selecting human antibodies from antibody libraries is described below.

[0334] In some embodiments of any of the antibodies provided herein, the antibody is a human antibody isolated by in vitro methods and / or screening of combinatorial libraries for antibodies having the desired activity. Suitable examples include, but are not limited to, phage display (CAT, Morphosys, Dyax, Biosite / Medarex, Xoma, Symphogen, Alexion (formerly Proliferon), Affimed), ribosome display (CAT), yeast display (Adimab), and the like. In certain phage display methods, libraries of VH and VL genes are cloned separately by polymerase chain reaction (PCR), and the libraries of VH and VL genes are randomly recombined in a phage library, which can then be screened for antigen binding phage as described in Winter et al. Ann. Rev. Immunol. 12: 433-455 (1994). For example, a variety of methods are known in the art for generating phage display libraries and screening such antibody libraries for desired binding properties. See also Sidhu et al. J. Mol. Biol. 338(2):299-310, 2004; Lee et al. J. Mol. Biol. 340(5):1073-1093, 2004; Fellouse Proc. Natl. Acad. Sci. USA 101(34):12467-12472 (2004); and Lee et al. J. Immunol. Methods 284(-2):119-132 (2004). Phage typically display antibody fragments in the form of single-chain antibody Fv (scFv) fragments or Fab fragments. Libraries from immunized sources provide high-affinity antibodies to the immunogen without the need to construct hybridomas. Alternatively, as described in Griffiths et al. EMBO J. 12: 725-734 (1993), it is possible to clone (e.g., from humans) a naive repertoire to provide a single antibody source for various non-self antigens and self antigens without any immunization. Finally, the original library can also be produced synthetically by cloning unrearranged V gene segments from stem cells and using PCR primers comprising random sequences to encode highly variable HVR3 regions and completing rearrangement in vitro, as described in Hoogenboom et al. J. Mol. Biol., 227: 381-388, 1992. Patent publications describing human antibody phage libraries include, for example, U.S. Patent No. 5,750,373, U.S. Patent Publication No. 2007 / 0292936 and No. 2009 / 0002360. Antibodies separated from human antibody libraries are considered herein to be human antibodies or human antibody fragments.

[0335] Constant region including Fc region

[0336] In certain embodiments, the anti-CD33 antibodies are antagonistic antibodies. In certain embodiments, the anti-CD33 antibodies are agonistic antibodies or inert antibodies. In some embodiments, the anti-CD33 antibodies of the present disclosure belong to the IgG class, the IgM class, or the IgA class. In some embodiments, the anti-CD33 antibodies of the present disclosure belong to the IgG class and have an IgG1, IgG2, IgG3, or IgG4 isotype. In some embodiments of any of the antibodies provided herein, the antibody comprises an Fc. In some embodiments, the Fc is a human IgG1, IgG2, IgG3, and / or IgG4 isotype. In some embodiments, the antibody belongs to the IgG class, the IgM class, or the IgA class.

[0337] In certain embodiments, the Fc region comprises an Fc variant listed below in Table E. The Fc variant may or may not have a C-terminal lysine residue, as shown in Table E.

[0338] Table E: Human Fc variants

[0339]

[0340]

[0341]

[0342]

[0343]

[0344] Additional anti-CD33 antibodies, such as antibodies that specifically bind to a CD33 protein of the present disclosure, can be identified, screened, and / or characterized for their physical / chemical properties and / or biological activities by various assays known in the art.

[0345] Anti-CD33 antibodies that bind to Fcγ receptors

[0346] In some embodiments, the anti-CD33 antibodies of the present disclosure retain the ability to bind to Fcγ receptors. In some embodiments, when such antibodies possess the correct epitope specificity compatible with receptor activation, they may possess characteristics that enable them to cluster and transiently stimulate, for example, the CD33 receptor. In some embodiments, such antibodies may then act as long-term inhibitors of CD33 expression and / or one or more activities of the CD33 protein by inducing CD33 degradation, CD33 desensitization, CD33 cleavage, CD33 internalization, CD33 shedding, downregulation of CD33 expression, and / or lysosomal degradation of CD33.

[0347] In vivo, the anti-CD33 antibodies of the present disclosure can cluster receptors and transiently activate CD33 through any one or more of a variety of potential mechanisms. Some isotypes of human antibodies, such as IgG2, have an intrinsic ability to cluster receptors or retain receptors in a clustered configuration due to their unique structure, thereby transiently activating receptors (such as CD33) without binding to Fc receptors (e.g., White et al., (2015) Cancer Cell 27, 138-148).

[0348] In some embodiments, other antibodies can cluster receptors (e.g., CD33) by binding to Fcg receptors on adjacent cells. In some embodiments, binding of the constant IgG Fc region of an antibody to an Fcg receptor can lead to aggregation of antibodies, which in turn can aggregate with the receptors to which they bind through their variable regions (Chu et al. (2008) Mol Immunol, 45:3926-3933; and Wilson et al. (2011) Cancer Cell 19, 101–113). In some embodiments, binding to the inhibitory Fcg receptor FcgR (FcgRIIB), which does not induce cytokine secretion, oxidative burst, enhanced phagocytosis, and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), is a preferred way to cluster antibodies in vivo because binding to FcgRIIB is not associated with adverse immune response effects.

[0349] The anti-CD33 antibodies of the present disclosure can cluster receptors by other mechanisms. For example, as described above, cross-linked antibody fragments (e.g., Fab fragments) can be used to cluster receptors (e.g., CD33) in a manner similar to antibodies with Fc regions that bind to Fcg receptors. In some embodiments, if cross-linked antibody fragments (e.g., Fab fragments) induce receptor clustering on the cell surface and bind to the appropriate epitope on the target (e.g., CD33), they can be used temporarily as agonistic antibodies.

[0350] Thus, in some embodiments, antibodies of the present disclosure that bind to CD33 protein may include antibodies that, due to their epitope specificity, bind to CD33 and transiently activate one or more CD33 activities before, for example, reducing cellular levels of CD33, inhibiting one or more CD33 activities, and / or inhibiting the interaction (e.g., binding) between CD33 and one or more CD33 ligands. In some embodiments, such antibodies may bind to the ligand binding site on CD33 and transiently mimic the effects of the natural ligand, or stimulate target antigen transduction signaling by binding to one or more domains that are not ligand binding sites. In some embodiments, such antibodies do not interfere with ligand binding. In some embodiments, regardless of whether the antibody binds to the ligand binding site on CD33, the antibody may subsequently act as a long-term inhibitor of CD33 expression and / or one or more activities of the CD33 protein by inducing CD33 degradation, CD33 desensitization, CD33 cleavage, CD33 internalization, CD33 shedding, downregulation of CD33 expression, and / or lysosomal degradation of CD33.

[0351] In some embodiments, the anti-CD33 antibodies of the present disclosure are antibodies that transiently induce one or more activities of the CD33 protein. In some embodiments, the antibody transiently induces one or more activities after binding to the CD33 protein expressed in the cell. In some embodiments, the CD33 protein is expressed on the surface of the cell. In some embodiments, the one or more activities of the CD33 protein transiently induced by the anti-CD33 antibodies of the present disclosure may include, but are not limited to, phosphorylation of Tyr-340 and Tyr-358 by Src family tyrosine kinases (such as LCK and FYN); recruitment and binding of tyrosine-specific protein phosphatases SHP1 and SHP2; recruitment and binding of PLC-γ1, which can serve as a guanine nucleotide exchange factor for dynamin-1; recruitment and binding of proteins containing SH2 domains (e.g., Crk1); recruitment and binding of spleen tyrosine kinase Syk; recruitment and binding of SH3-SH2-SH3 growth factor Recruitment and binding of receptor-binding protein 2 (Grb2); recruitment and binding of multiple SH2-containing proteins; phosphorylation of Ser-307 and Ser-342 by protein kinase C; regulation of expression of one or more soluble receptors for the anti-inflammatory cytokines IL-4, IL-10, IL-13, IL-35, IL-16, TGF-β, IL-1Ra, G-CSF, and TNF, INF-β1a, INF-β1b, or IL-6 in monocytes, macrophages, T cells, dendritic cells, neutrophils, and / or microglia; reduction of intracellular calcium mobilization; Regulate the expression of one or more proinflammatory cytokines IFN-a4, IFN-b, IL-1β, TNF-α, IL-6, IL-8, CRP, IL-20 family members, LIF, IFN-γ, OSM, CNTF, GM-CSF, IL-11, IL-12, IL-17, IL-18, IL-23, CXCL10, IL-33, CRP, IL-33, MCP-1 and MIP-1-β in cells, neutrophils and / or microglial cells; regulate one or more selected from C1qa, C1qB, C1qC, C1s, C1R, C4, C2, C3, ITGB2 , HMOX1, LAT2, CASP1, CSTA, VSIG4, MS4A4A, C3AR1, GPX1, TyroBP, ALOX5AP, ITGAM, SLC7A7, CD4, ITGAX, PYCARD, CD14, CD16, HLA-DR and CCR2 protein expression; inhibit extracellular signal-regulated kinase (ERK) phosphorylation; reduce tyrosine phosphorylation on multiple cellular proteins; regulate CC chemokine receptor 7 (CCR7) expression; inhibit microglial chemotaxis towards cells expressing CCL19 and CCL21; activate phosphoinositide 3-kinase;Reduce cell growth of monocytes, macrophages, T cells, dendritic cells and / or microglia; reduce T cell proliferation induced by dendritic cells, bone marrow-derived dendritic cells, monocytes, microglia, M1 microglia, activated M1 microglia, M2 microglia, macrophages, M1 macrophages, activated M1 macrophages and / or M2 macrophages; inhibit osteoclast production, reduce the rate of osteoclast formation, or both; reduce the number of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, T helper cells, The drug may also inhibit the proliferation of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia; inhibit the proliferation of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia; inhibit the proliferation of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages the migration of neutrophils, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia and / or M2 microglia; reduce one or more functions of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia and / or M2 microglia; inhibit neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia and / or M2 microglia; inhibit neutrophils, dendritic cells, bone marrow-derived dendritic cells, the maturation of monocytes, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia and / or M2 microglia; increasing cell death and apoptosis of monocytes, macrophages, T cells, dendritic cells, neutrophils and / or microglia; decreasing the phagocytic activity of monocytes, macrophages, T cells, dendritic cells, neutrophils and / or microglia; decreasing the proliferation of monocytes, macrophages, T cells, dendritic cells, neutrophils and / or microglia;Reduce the overall function of monocytes, macrophages, T cells, dendritic cells, neutrophils and / or microglia; phosphorylate ITAM-containing receptors; phosphorylate signaling molecules that mediate ITAM signaling; reduce the activation of pattern recognition receptors; reduce the activation of Toll-like receptors; reduce damage-associated activation of cell and protein debris clearance; interaction between CD33 and one or more of its ligands; interaction between CD33 and co-receptors such as CD64; reduce clearance of apoptotic neurons, clearance of neural tissue debris, clearance of dysfunctional synapses, clearance of non-neural tissue debris, bacteria or other foreign matter one or more of apoptotic neurons, neural tissue fragments, non-neural tissue fragments, bacteria, other foreign matter, pathogenic proteins, pathogenic peptides, pathogenic nucleic acids, pathogenic lipids or tumor cells; inhibiting the clearance of pathogenic nucleic acids (such as pathogenic nucleic acids are antisense GGCCCC (G2C4) repeat expansion RNA); activating a protein selected from beta-amyloid protein, beta-amyloid plaques, amyloid precursor protein or fragments thereof, Tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin protein, calcitonin, superoxide dismutase, ataxia, ataxia 1, ataxia 2, ataxia 3, ataxia 7, ataxia 8, ataxia 10, Lewy bodies, atrial natriuretic peptide, islet amyloid polypeptide, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, β2-microglobulin, gelsolin, keratoepithelin, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) transversion the clearance of pathogenic proteins such as leukemia, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, acute myeloid leukemia, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, and thyroid cancer;Suppressing beneficial immune responses to different types of neurological disorders selected from dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, amyotrophic lateral sclerosis, Huntington's disease, tauopathy, Nasu-Hakola disease, stroke, acute trauma, chronic trauma, essential tremor, Behcet's disease, Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, Shy-Drager syndrome, progressive supranuclear palsy, corticobasal ganglionic degeneration, acute disseminated encephalomyelitis, granulomatous disorders, sarcoidosis, diseases of aging, epilepsy, spinal cord injury, traumatic brain injury, age-related macular degeneration, glaucoma, retinitis pigmentosa, retinal degeneration and multiple sclerosis inhibiting beneficial immune responses to different types of inflammatory and infectious conditions selected from lupus, acute and chronic colitis, wound healing, Crohn's disease, inflammatory bowel disease, ulcerative colitis, obesity, malaria, respiratory tract infections, sepsis, eye infections, systemic infections, lupus, arthritis, low bone density, osteoporosis, osteogenesis, osteosclerotic diseases, and Paget's disease of bone; inhibiting phagocytosis of one or more of apoptotic neurons, neural tissue debris, dysfunctional synapses, non-neural tissue debris, bacteria, other foreign matter, pathogenic proteins, pathogenic peptides, pathogenic nucleic acids, or tumor cells, wherein the pathogenic nucleic acid can be an antisense GGCCCC (G2C4) repeat expanded RNA and the pathogenic protein can include β-amyloid. amyloid, oligomeric beta-amyloid, beta-amyloid plaques, amyloid precursor protein or its fragments, Tau, IAPP, alpha-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), C9RAN protein, prion protein, PrPSc, huntingtin protein, calcitonin, superoxide dismutase, ataxia, ataxia 1, ataxia 2, ataxia 3, ataxia 7, ataxia 8, ataxia 10, Lewy bodies, atrial natriuretic peptide, islet amyloid polypeptide, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, beta-2 microglobulin, gelsin Elimination of pathogenic proteins such as collagen, keratoepithelin, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation products, dipeptide repeat (DPR) peptides, glycine-alanine (GA) repeat peptides, glycine-proline (GP) repeat peptides, glycine-arginine (GR) repeat peptides, proline-alanine (PA) repeat peptides, ubiquitin and proline-arginine (PR) repeat peptides; and the tumor cells may be from a cancer selected from bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma and thyroid cancer;Binds to CD33 ligands on tumor cells; binds to CD33 ligands on dendritic cells, bone marrow-derived dendritic cells, monocytes, microglia, T cells, neutrophils and / or macrophages; inhibits tumor cell killing by one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells or cytotoxic T cells; inhibits anti-tumor cell proliferation by one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells or cytotoxic T cells inhibiting the anti-tumor cell metastatic activity of one or more of microglia, macrophages, dendritic cells, myeloid-derived dendritic cells, neutrophils, T cells, helper T cells or cytotoxic T cells; promoting immunosuppressive dendritic cells, immunosuppressive macrophages, myeloid-derived suppressor cells, tumor-associated macrophages or regulatory T cells; inhibiting one or more receptors containing ITAM motifs, such as TREM1, TREM2, FcgR, DAP10 and DAP12; inhibiting one or more receptors containing the motif D / Ex0–2YxxL / IX6–8YxxL / I (SEQ ID NO: 116) inhibiting signaling through one or more pattern recognition receptors (PRRs), such as receptors that recognize pathogen-associated molecular patterns (PAMPs) and receptors that recognize damage-associated molecular patterns (DAMPs); inhibiting signaling through one or more Toll-like receptors; inhibiting the JAK-STAT signaling pathway; inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB); inhibiting PLCγ / PKC / calcium mobilization; inhibiting PI3K / Akt, Ras / MAPK signaling; modulating the expression of one or more inflammatory receptors, such as CD86, expressed on one or more of microglia, macrophages, dendritic cells, myeloid-derived dendritic cells, neutrophils, T cells, helper T cells, or cytotoxic T cells; increasing the expression of one or more CD33-dependent genes; normalizing the expression of disrupted CD33-dependent genes;and reducing the expression of one or more ITAM-dependent genes, such as NFAT transcription factors. The ability of the anti-CD33 antibodies of the present disclosure to transiently induce one or more activities of the CD33 protein can be tested using any suitable technique or assay known in the art and disclosed herein. Regardless of the activity transiently induced by such antibodies, such antibodies can subsequently act as lo...

Claims

1. An isolated antibody that binds to a CD33 protein, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: HVR-H1 as shown in the amino acid sequence of SEQ ID NO:23, HVR-H2 as shown in the amino acid sequence of SEQ ID NO:33, and HVR-H3 as shown in the amino acid sequence of SEQ ID NO:39; and wherein the light chain variable region comprises: HVR-L1 as shown in the amino acid sequence of SEQ ID NO:47, HVR-L2 as shown in the amino acid sequence of SEQ ID NO:53, and HVR-L3 as shown in the amino acid sequence of SEQ ID NO:

61.

2. An isolated antibody that binds to a CD33 protein, wherein the antibody comprises A heavy chain variable region comprising the amino acid sequence of SEQ ID NO:83 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:

102.

3. An isolated antibody that binds to a CD33 protein, wherein the antibody comprises (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 120 and a light chain comprising the amino acid sequence of SEQ ID NO: 122; or (b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 121 and a light chain comprising the amino acid sequence of SEQ ID NO:

122.

4. A pharmaceutical composition comprising the antibody according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier.

5. Use of the antibody of any one of claims 1 to 3 or the pharmaceutical composition of claim 4 for the preparation of a medicament for use in a method for treating Alzheimer's disease, the method comprising administering a therapeutically effective amount of the antibody of any one of claims 1 to 3 or the pharmaceutical composition of claim 4 to an individual in need thereof.

6. The antibody according to claim 1 or 2, wherein the antibody is of the IgG class, the IgM class or the IgA class.

7. The antibody of claim 6, wherein the antibody is of the IgG class and has an IgG1, IgG2, IgG3 or IgG4 isotype.

8. The antibody of claim 7, wherein the antibody comprises one or more amino acid substitutions at a residue position in the Fc region selected from the group consisting of C127S, L234A, L234F, L235A, L235E, S267E, K322A, L328F, A330S, P331S, E345R, E430G, S440Y, and any combination thereof, wherein the numbering of the residues is according to EU numbering.

9. The antibody of claim 7, wherein the antibody has an IgG4 isotype, and wherein the antibody comprises an S228P amino acid substitution at residue position 228, a F234A amino acid substitution at residue position 234, and a L235A amino acid substitution at residue position 235, wherein the numbering of the residue positions is according to EU numbering.

10. The antibody according to claim 9, in: (a) the Fc region comprises an amino acid substitution at position E430G, wherein the numbering of residue positions is according to EU numbering; (b) the Fc region comprises amino acid substitutions at positions L234A, L235A and P331A, wherein the numbering of the residue positions is according to EU numbering; (c) the Fc region comprises amino acid substitutions at positions L234A, L235A, P331A and E430G, wherein the numbering of the residue positions is according to EU numbering; (d) the Fc region comprises amino acid substitutions at positions K322A and E430G, wherein the numbering of the residue positions is according to EU numbering; (e) the Fc region comprises amino acid substitutions at positions P331S and E430G, wherein the numbering of the residue positions is according to EU numbering; (f) the Fc region comprises amino acid substitutions at positions A330S, P331S, and E430G, wherein the numbering of the residue positions is according to EU numbering; (g) the Fc region comprises amino acid substitutions at positions K322A, A330S, and P331S, wherein the numbering of the residue positions is according to EU numbering; (h) the Fc region comprises amino acid substitutions at positions K322A, P331S, and E430G, wherein the numbering of the residue positions is according to EU numbering; (i) the Fc region comprises an amino acid substitution at position E430G, wherein the numbering of residue positions is according to EU numbering; (j) the Fc region comprises amino acid substitutions at positions A330S, P331S, and E430G, wherein the numbering of the residue positions is according to EU numbering; (k) the Fc region comprises amino acid substitutions at positions S267E and L328F, wherein the numbering of the residue positions is according to EU numbering; (1) the Fc region comprises an amino acid substitution at position C127S, wherein the numbering of the residue positions is according to EU numbering; (m) the Fc region comprises amino acid substitutions at positions E345R, E430G, and S440Y, wherein the numbering of the residue positions is according to EU numbering; (n) the Fc region comprises an amino acid substitution at position P331S, wherein the numbering of residue positions is according to EU numbering; or (o) the Fc region comprises amino acid substitutions at positions L234A, L235A, P331S, wherein the numbering of the residue positions is according to EU numbering.

11. The antibody of any one of claims 1-3, wherein the CD33 protein is cynomolgus monkey CD33 protein or human CD33 protein.

12. The antibody of any one of claims 1-3, wherein the CD33 protein is a wild-type protein.

13. The antibody of any one of claims 1-3, wherein the CD33 protein is a naturally occurring variant.

14. The antibody of any one of claims 1-3, wherein the CD33 protein is expressed on one or more cells selected from the group consisting of: human dendritic cells, human macrophages, human monocytes, human osteoclasts, human neutrophils, human T cells, human granulocytes, and human microglia.

15. The antibody of claim 14, wherein the CD33 protein is expressed on human helper T cells and / or human cytotoxic T cells.

16. The antibody of any one of claims 1-3, wherein the antibody specifically binds to human CD33 protein.

17. The antibody of claim 1 or 2, wherein the antibody is an antibody fragment that binds to an epitope comprising amino acid residues on a human CD33 protein or a cynomolgus monkey CD33 protein.

18. The antibody of claim 1 or 2, wherein the antibody is an antibody fragment that binds to one or more human proteins selected from the group consisting of: human CD33, naturally occurring variants of human CD33, and disease variants of human CD33.

19. The antibody of claim 17, wherein the antibody fragment is cross-linked to a second antibody fragment that binds to one or more human proteins selected from the group consisting of: human CD33, naturally occurring variants of human CD33, and disease variants of human CD33.

20. The antibody of claim 17, wherein the fragment is a Fab, Fab', Fab'-SH, F(ab')2, Fv or scFv fragment.

21. The antibody of any one of claims 1-3, wherein the antibody is a humanized antibody, a bispecific antibody, a monoclonal antibody, a multivalent antibody, a conjugated antibody, or a chimeric antibody.

22. The antibody of any one of claims 1-3, wherein the antibody is a monoclonal antibody.

23. The antibody of claim 1 or 2, wherein the antibody is a bispecific antibody that recognizes a first antigen and a second antigen.

24. The antibody of claim 23, wherein the first antigen is CD33 and the second antigen is: (a) antigens that promote transport across the blood-brain barrier; (b) an antigen that promotes transport across the blood-brain barrier selected from the group consisting of transferrin receptor (TR), insulin receptor (HIR), insulin-like growth factor receptor (IGFR), low-density lipoprotein receptor-related proteins 1 and 2 (LPR-1 and LPR-2), diphtheria toxin receptor, CRM197, alpaca single domain antibody, TMEM 30 (A), protein transduction domain, TAT, Syn-B, penetratin, polyarginine peptide, angiopep peptide and ANG1005; (c) a pathogenic factor selected from the group consisting of amyloid β, amyloid precursor protein or a fragment thereof, Tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin, calcitonin, superoxide dismutase, ataxia, Lewy body, atrial natriuretic peptide, islet amylin, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, β2 microglobulin, gelsolin, keratoepithelin, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation product, dipeptide repeat (DPR) peptide, ubiquitin and antisense GGCCCC (G2C4) repeat expansion RNA; (d) a ligand and / or protein expressed on an immune cell, wherein the ligand and / or protein is selected from the group consisting of CD40, OX40, ICOS, CD28, CD137 / 4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7-H4, HVEM, LIGHT, BTLA, CD38, TIGIT, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR, LAG3, DR5, CD39, CD70, CD73, TREM1, TREM2, Siglec-5, Siglec-7, Siglec-9, Siglec-11, SirpA, CD47, CSF1-receptor, and phosphatidylserine; or (e) a protein, lipid or polysaccharide expressed on one or more tumor cells.

25. The antibody according to claim 24, in: (a) the amyloid β protein is oligomeric amyloid β protein or amyloid β protein plaque; (b) the ataxin is selected from the group consisting of ataxin 1, ataxin 2, ataxin 3, ataxin 7, ataxin 8 and ataxin 10; (c) the dipeptide repeat (DPR) peptide is selected from the group consisting of a glycine-alanine (GA) repeat peptide, a glycine-proline (GP) repeat peptide, a glycine-arginine (GR) repeat peptide, a proline-alanine (PA) repeat peptide, and a proline-arginine (PR) repeat peptide; or (d) The lipid is a glycolipid.

26. The antibody of any one of claims 1-3, wherein the antibody is used in combination with one or more antibodies that specifically bind to a pathogenic factor, the pathogenic factor being selected from the group consisting of: beta amyloid, amyloid precursor protein or a fragment thereof, Tau, IAPP, alpha-synuclein, TDP-43, FUS protein, C9orf72 (open reading frame 72 of chromosome 9), prion protein, PrPSc, huntingtin, calcitonin, superoxide dismutase, ataxia, Lewy bodies, atrial natriuretic peptide, islet amylin, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, beta 2 microglobulin, gelsolin, keratoepithelin, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation products, dipeptide repeat (DPR) peptides, ubiquitin and any combination thereof; or used in combination with one or more antibodies that bind to immunomodulatory proteins, wherein the immunomodulatory proteins are selected from the group consisting of CD40, OX40, ICOS, CD28, CD137 / 4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7-H4, HVEM, LIGHT, BTLA, CD38, TIGIT, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR3, DR5, CD39, CD70, CD73, LAG3, TREM1, TREM2, Siglec-5, Siglec-7, Siglec-9, Siglec-11, SirpA, CD47, CSF1-receptor, phosphatidylserine, antisense GGCCCC (G2C4) repeat expansion RNA, and any combination thereof.

27. The antibody according to claim 26, in: (a) the amyloid β protein is oligomeric amyloid β protein or amyloid β protein plaque; (b) the ataxin is selected from the group consisting of ataxin 1, ataxin 2, ataxin 3, ataxin 7, ataxin 8, ataxin 10, and any combination thereof; or (c) The dipeptide repeat (DPR) peptide is selected from the group consisting of glycine-alanine (GA) repeat peptides, glycine-proline (GP) repeat peptides, glycine-arginine (GR) repeat peptides, proline-alanine (PA) repeat peptides and proline-arginine (PR) repeat peptides and any combination thereof.

28. The antibody of any one of claims 1-3, wherein the dissociation constant (K) of the antibody for human CD33 is D ) is at least 1.8 times lower than an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4, wherein the K D Determined by biofilm interferometry.

29. The antibody of any one of claims 1-3, wherein the dissociation constant (K) of the antibody for human CD33 is D ) is 200 pM, or less than 200 pM, and wherein the K D Determined by biofilm interferometry.

30. The antibody of any one of claims 1-3, wherein the antibody reduces cell surface levels of CD33.

31. The antibody of claim 30, wherein the CD33 is expressed on the surface of human dendritic cells.

32. The antibody of claim 30, wherein the antibody reduces cell surface levels of CD33 in vitro.

33. The antibody of any one of claims 30-32, wherein the antibody has an in vitro half-maximal effective concentration (EC) of less than 40 pM as measured by flow cytometry. 50 ) reduces the cell surface levels of CD33.

34. The antibody of any one of claims 1-3, wherein the antibody increases the expression of one or more disease-associated microglial (DAM) markers.

35. The antibody of claim 34, wherein the one or more DAM markers are ApoE3, Tyrobp, B2m, Trem2, Cst7, Ctsl, Lpl, Cd9, Axl, Csf1, Ccl6, Itgax, Clec7a, Lilrb4, Timp2, or any combination thereof.

36. The antibody of claim 1 or 2, wherein the antibody comprises an Fc region comprising the amino acid sequence of SEQ ID NO:

118.

37. An isolated nucleic acid comprising a nucleic acid sequence encoding the antibody of any one of claims 1-3.

38. A vector comprising the nucleic acid of claim 37.

39. An isolated host cell comprising the vector of claim 38.

40. A method for producing an antibody that binds to a CD33 protein, the method comprising culturing the cell of claim 39, thereby producing the antibody.

41. The method of claim 40, further comprising recovering the antibody produced by the cell.

42. An isolated antibody that binds to a CD33 protein, wherein the antibody is produced by the method of claim 40 or claim 41.

43. The antibody of any one of claims 1-3, wherein the antibody has an IgG2 isotype.